CA3138296A1 - Method for preventing the formation of calcified deposits and for inactivating xenoantigens in biological matrices - Google Patents
Method for preventing the formation of calcified deposits and for inactivating xenoantigens in biological matrices Download PDFInfo
- Publication number
- CA3138296A1 CA3138296A1 CA3138296A CA3138296A CA3138296A1 CA 3138296 A1 CA3138296 A1 CA 3138296A1 CA 3138296 A CA3138296 A CA 3138296A CA 3138296 A CA3138296 A CA 3138296A CA 3138296 A1 CA3138296 A1 CA 3138296A1
- Authority
- CA
- Canada
- Prior art keywords
- acid
- solution
- biological matrix
- mixture
- treated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 78
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 29
- 230000000415 inactivating effect Effects 0.000 title description 5
- 239000011159 matrix material Substances 0.000 claims abstract description 55
- 150000002989 phenols Chemical class 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 239000000243 solution Substances 0.000 claims description 40
- 210000001519 tissue Anatomy 0.000 claims description 39
- 150000002632 lipids Chemical class 0.000 claims description 18
- 210000003709 heart valve Anatomy 0.000 claims description 16
- 208000007536 Thrombosis Diseases 0.000 claims description 14
- 230000001413 cellular effect Effects 0.000 claims description 13
- 235000013824 polyphenols Nutrition 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- 230000008595 infiltration Effects 0.000 claims description 12
- 238000001764 infiltration Methods 0.000 claims description 12
- 229930015704 phenylpropanoid Natural products 0.000 claims description 11
- -1 cyanarin Chemical compound 0.000 claims description 10
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 9
- 125000001474 phenylpropanoid group Chemical group 0.000 claims description 9
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 8
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 claims description 8
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 8
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 8
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 7
- 208000019622 heart disease Diseases 0.000 claims description 7
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- KZMACGJDUUWFCH-UHFFFAOYSA-O malvidin Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KZMACGJDUUWFCH-UHFFFAOYSA-O 0.000 claims description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 claims description 6
- 229920002258 tannic acid Polymers 0.000 claims description 6
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 5
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 5
- AFHJQYHRLPMKHU-XXWVOBANSA-N Aloin Natural products O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)c2c1c(O)ccc2 AFHJQYHRLPMKHU-XXWVOBANSA-N 0.000 claims description 5
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 5
- 239000001263 FEMA 3042 Substances 0.000 claims description 5
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 5
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 5
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 5
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 5
- CPUHNROBVJNNPW-UHFFFAOYSA-N aloin A Natural products OC1C(O)C(O)C(CO)OC1OC1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 CPUHNROBVJNNPW-UHFFFAOYSA-N 0.000 claims description 5
- AFHJQYHRLPMKHU-WEZNYRQKSA-N aloin B Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-WEZNYRQKSA-N 0.000 claims description 5
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 5
- 229940074393 chlorogenic acid Drugs 0.000 claims description 5
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 5
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 5
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 5
- 235000004515 gallic acid Nutrition 0.000 claims description 5
- 229940074391 gallic acid Drugs 0.000 claims description 5
- AFHJQYHRLPMKHU-UHFFFAOYSA-N isobarbaloin Natural products OC1C(O)C(O)C(CO)OC1C1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-UHFFFAOYSA-N 0.000 claims description 5
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 5
- 235000021283 resveratrol Nutrition 0.000 claims description 5
- 229940016667 resveratrol Drugs 0.000 claims description 5
- 235000015523 tannic acid Nutrition 0.000 claims description 5
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 5
- 229940033123 tannic acid Drugs 0.000 claims description 5
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 4
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 claims description 4
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims description 4
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 4
- 235000004883 caffeic acid Nutrition 0.000 claims description 4
- 229940074360 caffeic acid Drugs 0.000 claims description 4
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 4
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims description 4
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 claims description 4
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 claims description 4
- 235000010209 hesperetin Nutrition 0.000 claims description 4
- 229960001587 hesperetin Drugs 0.000 claims description 4
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 claims description 4
- 235000003248 hydroxytyrosol Nutrition 0.000 claims description 4
- 229940095066 hydroxytyrosol Drugs 0.000 claims description 4
- 238000002513 implantation Methods 0.000 claims description 4
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 claims description 4
- 235000007625 naringenin Nutrition 0.000 claims description 4
- 229940117954 naringenin Drugs 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 4
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 4
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 claims description 3
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 claims description 3
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 3
- YDDGKXBLOXEEMN-IABMMNSOSA-L Chicoric acid Natural products C1=C(O)C(O)=CC=C1\C=C\C(=O)O[C@@H](C([O-])=O)[C@H](C([O-])=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-L 0.000 claims description 3
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 claims description 3
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 claims description 3
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 claims description 3
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 3
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 claims description 3
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 claims description 3
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 claims description 3
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 claims description 3
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 claims description 3
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims description 3
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims description 3
- 235000008714 apigenin Nutrition 0.000 claims description 3
- 229940117893 apigenin Drugs 0.000 claims description 3
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 3
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 claims description 3
- 229930016920 cichoric acid Natural products 0.000 claims description 3
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 3
- 235000007240 daidzein Nutrition 0.000 claims description 3
- 235000007242 delphinidin Nutrition 0.000 claims description 3
- YDDGKXBLOXEEMN-PMACEKPBSA-N dicaffeoyl-D-tartaric acid Natural products O([C@H](C(=O)O)[C@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-PMACEKPBSA-N 0.000 claims description 3
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 claims description 3
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 claims description 3
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 claims description 3
- 235000011797 eriodictyol Nutrition 0.000 claims description 3
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 claims description 3
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 3
- 235000001785 ferulic acid Nutrition 0.000 claims description 3
- 229940114124 ferulic acid Drugs 0.000 claims description 3
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 3
- 229930003935 flavonoid Natural products 0.000 claims description 3
- 150000002215 flavonoids Chemical class 0.000 claims description 3
- 235000017173 flavonoids Nutrition 0.000 claims description 3
- 235000006539 genistein Nutrition 0.000 claims description 3
- 229940045109 genistein Drugs 0.000 claims description 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 3
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 3
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 claims description 3
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 claims description 3
- 235000008466 glycitein Nutrition 0.000 claims description 3
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 3
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 3
- 229940025878 hesperidin Drugs 0.000 claims description 3
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000008800 isorhamnetin Nutrition 0.000 claims description 3
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 3
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000009498 luteolin Nutrition 0.000 claims description 3
- 235000009584 malvidin Nutrition 0.000 claims description 3
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 claims description 3
- 235000007743 myricetin Nutrition 0.000 claims description 3
- 229940116852 myricetin Drugs 0.000 claims description 3
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- HKUHOPQRJKPJCJ-UHFFFAOYSA-N pelargonidin Natural products OC1=Cc2c(O)cc(O)cc2OC1c1ccc(O)cc1 HKUHOPQRJKPJCJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000006251 pelargonidin Nutrition 0.000 claims description 3
- 210000003516 pericardium Anatomy 0.000 claims description 3
- 150000007965 phenolic acids Chemical class 0.000 claims description 3
- 235000009048 phenolic acids Nutrition 0.000 claims description 3
- 235000007221 pinoresinol Nutrition 0.000 claims description 3
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 claims description 3
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 claims description 3
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- 235000008603 tangeritin Nutrition 0.000 claims description 3
- 229920001864 tannin Polymers 0.000 claims description 3
- 235000018553 tannin Nutrition 0.000 claims description 3
- 239000001648 tannin Substances 0.000 claims description 3
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 claims description 3
- 235000014620 theaflavin Nutrition 0.000 claims description 3
- 229940026509 theaflavin Drugs 0.000 claims description 3
- 235000008118 thearubigins Nutrition 0.000 claims description 3
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 3
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 claims description 3
- 241001269524 Dura Species 0.000 claims description 2
- 230000003187 abdominal effect Effects 0.000 claims description 2
- 210000000577 adipose tissue Anatomy 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 210000003041 ligament Anatomy 0.000 claims description 2
- 230000003387 muscular Effects 0.000 claims description 2
- 229930015721 peonidin Natural products 0.000 claims description 2
- 235000006404 peonidin Nutrition 0.000 claims description 2
- 210000004876 tela submucosa Anatomy 0.000 claims description 2
- 210000002435 tendon Anatomy 0.000 claims description 2
- 210000003454 tympanic membrane Anatomy 0.000 claims description 2
- 239000011534 wash buffer Substances 0.000 claims description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims 4
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims 2
- JKHRCGUTYDNCLE-UHFFFAOYSA-O delphinidin Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 JKHRCGUTYDNCLE-UHFFFAOYSA-O 0.000 claims 2
- 235000008777 kaempferol Nutrition 0.000 claims 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims 2
- XVFMGWDSJLBXDZ-UHFFFAOYSA-O pelargonidin Chemical compound C1=CC(O)=CC=C1C(C(=C1)O)=[O+]C2=C1C(O)=CC(O)=C2 XVFMGWDSJLBXDZ-UHFFFAOYSA-O 0.000 claims 2
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 101100314144 Mus musculus Tnip1 gene Proteins 0.000 claims 1
- SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- XFDQJKDGGOEYPI-UHFFFAOYSA-O peonidin Chemical compound C1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 XFDQJKDGGOEYPI-UHFFFAOYSA-O 0.000 claims 1
- 239000011575 calcium Substances 0.000 description 26
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 25
- 229910052791 calcium Inorganic materials 0.000 description 25
- 101000718529 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Alpha-galactosidase Proteins 0.000 description 18
- NNISLDGFPWIBDF-MPRBLYSKSA-N alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 NNISLDGFPWIBDF-MPRBLYSKSA-N 0.000 description 18
- 241000282898 Sus scrofa Species 0.000 description 16
- 238000010186 staining Methods 0.000 description 16
- 208000004434 Calcinosis Diseases 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 241001111421 Pannus Species 0.000 description 10
- 230000002308 calcification Effects 0.000 description 10
- 230000008021 deposition Effects 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 238000011002 quantification Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 238000009616 inductively coupled plasma Methods 0.000 description 9
- 150000008442 polyphenolic compounds Chemical class 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 206010067171 Regurgitation Diseases 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000007704 transition Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 208000005422 Foreign-Body reaction Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003176 fibrotic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000541 pulsatile effect Effects 0.000 description 4
- ODDPRQJTYDIWJU-UHFFFAOYSA-N 3'-beta-D-galactopyranosyl-lactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C1O ODDPRQJTYDIWJU-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003169 alpha-Gal epitope group Chemical group [C@H]1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@@H]1O)CO)O[C@H]1[C@@H]([C@H](C(O[C@@H]1CO)*)NC(C)=O)O)O 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000010065 bacterial adhesion Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000003185 calcium uptake Effects 0.000 description 3
- 235000005487 catechin Nutrition 0.000 description 3
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000004177 elastic tissue Anatomy 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000001974 tryptic soy broth Substances 0.000 description 3
- 108010050327 trypticase-soy broth Proteins 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091035710 E-box Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000000181 anti-adherent effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- ZEACOKJOQLAYTD-UHFFFAOYSA-N flavan-3,3',4,4',5,5',7-heptol Chemical compound OC1C(O)C2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 ZEACOKJOQLAYTD-UHFFFAOYSA-N 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- YDDUMTOHNYZQPO-UHFFFAOYSA-N 1,3-bis{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4,5-dihydroxycyclohexanecarboxylic acid Natural products OC1C(O)CC(C(O)=O)(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-UHFFFAOYSA-N 0.000 description 1
- ZXVONLUNISGICL-UHFFFAOYSA-N 4,6-dinitro-o-cresol Chemical compound CC1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O ZXVONLUNISGICL-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- SITQVDJAXQSXSA-CEZRHVESSA-N Cynarin Natural products O[C@@H]1C[C@@](C[C@H](O)[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)(OC(=O)C=Cc3cccc(O)c3O)C(=O)O SITQVDJAXQSXSA-CEZRHVESSA-N 0.000 description 1
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical compound O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010090758 L-gulonolactone oxidase Proteins 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 108010029541 Laccase Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000582 anti-calcifiying effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000001201 calcium accumulation Effects 0.000 description 1
- 159000000007 calcium salts Chemical group 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 150000001789 chalcones Chemical class 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid group Chemical class C(C=CC1=CC=CC=C1)(=O)O WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229950009125 cynarine Drugs 0.000 description 1
- YDDUMTOHNYZQPO-BKUKFAEQSA-N cynarine Natural products O[C@H]1C[C@@](C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O YDDUMTOHNYZQPO-BKUKFAEQSA-N 0.000 description 1
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 229930003939 flavanonol Natural products 0.000 description 1
- 150000002210 flavanonols Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 1
- DEDGUGJNLNLJSR-UHFFFAOYSA-N hydroxycinnamic acid group Chemical class OC(C(=O)O)=CC1=CC=CC=C1 DEDGUGJNLNLJSR-UHFFFAOYSA-N 0.000 description 1
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000007433 macroscopic evaluation Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000001453 nonthrombogenic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- YPVZJXMTXCOTJN-UHFFFAOYSA-N pelargonidin chloride Chemical compound [Cl-].C1=CC(O)=CC=C1C(C(=C1)O)=[O+]C2=C1C(O)=CC(O)=C2 YPVZJXMTXCOTJN-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- OGBSHLKSHNAPEW-UHFFFAOYSA-N peonidin chloride Chemical compound [Cl-].C1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 OGBSHLKSHNAPEW-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000721 toxic potential Toxicity 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 150000007964 xanthones Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3625—Vascular tissue, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/02—Treatment of implants to prevent calcification or mineralisation in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Abstract
The present invention discloses a method for preventing the formation of calcified deposits or inside an isolated biological matrix comprising the step of contacting said isolated biological matrix with a solution comprising a mixture of phenolic compounds.
Description
DESCRIPTION
"METHOD FOR PREVENTING THE FORMATION OF CALCIFIED DEPOSITS AND FOR
INACTIVATING XENOANTIGENS IN BIOLOGICAL MATRICES"
13ackoround of the invention The present invention finds application in the medical, biomedical or veterinary field and, in particular, in the preparation of biological and biocompatible matrices to be implanted in the human or animal body.
The production of bioprosthelic substitutes is currently undergoing a significant market expansion. The clinical improvement of surgical procedures, the decrease in post-surgical complications, the development and management of new immune-modulating medicine, combined with a more in-depth knowledge of the interaction mechanisms between graft and host, all contribute to facilitating the use of biological prostheses constituted by an animal or homologous tissue. In this sense, one sector that is representative is the cardiovascular sector, especially in terms of the social and health impact that the established practice of cardiac valve replacement can cause.
Biomedical technology is capable of developing and surgically applying valve prostheses for replacement that can imitate the opening and closing function of dysfunctional native valves. A
desirable bioprosthetic heart valve substitute (BHV) should be capable of allowing a trans-valve flow that can overlap that of the analogue original, healthy valve, to ensure a long lifetime and not generate haemolytic or thrombogenic effects.
The valve substitutes that are most often used are biological prostheses derived from xenogeneic tissues, in particular from pig valves or valves produced with the bovine, equine or porcine pericardium.
Such valve prostheses and substitutes suffer from many criticalities that severely imit their clinical application.
The international patent application WO 2017/093147 discloses a method for the inactivation of xenoantigens, and in particular of alpha-Gal, in biological tissues for the production of bioprostheses. Aspects relating to calcification are incidentally mentioned as proved by the absence of any experimental description supporting its effectiveness.
The US patent application US 2014/018909 discloses a method for preserving tissues intended for applications in the cardiovascular field, from the products of reactions that accumulate in patients with diabetes and, in particular, resulting from the oxidation of lipid components. These catabolic products are named as AGEs and are responsible for accelerating the degeneration mechanisms of bioprosthetic substitutes, such as vessels and heart valves, in diabetic patients.
The method is disclosed in connection with Pentagalfoylglucose ¨ PGG, only and it is performed on a collagen matrix obtained by decellularizing a porcine heart valve and an elastin matrix obtained by treating a previously decellularized porcine carotid artery with alkali.
The international patent application WO 01/21228 discloses the use of gallotanic acid to mitigate the calcification of biological or synthetic tissues that can be used for the production of head valve substitutes.
Summary of the invention The inventors of the present patent application have surprisingly found a method for increasing the biocompatibility of prostheses, particularly of cardiac prostheses. In particular, the increased biocompatibility comprises the increase in one or more of:
preventing the formation of calcified deposits, inactivating xenoantigens in biological matrices, preventing the thrombus formation in a biological matrix, preventing the lipid infiltration into a biological matrix, preventing the onset of inflammatory process mediated by the cellular component, prevents the biofouling processes on a biological matrix.
Brief description of the !mires Figure 1: results of the assays on the phenolic compound release.
Figure 2: results of the in-vitro calcification assays.
Figure 3: the valve placed in the custom-fabricated silicone holder.
"METHOD FOR PREVENTING THE FORMATION OF CALCIFIED DEPOSITS AND FOR
INACTIVATING XENOANTIGENS IN BIOLOGICAL MATRICES"
13ackoround of the invention The present invention finds application in the medical, biomedical or veterinary field and, in particular, in the preparation of biological and biocompatible matrices to be implanted in the human or animal body.
The production of bioprosthelic substitutes is currently undergoing a significant market expansion. The clinical improvement of surgical procedures, the decrease in post-surgical complications, the development and management of new immune-modulating medicine, combined with a more in-depth knowledge of the interaction mechanisms between graft and host, all contribute to facilitating the use of biological prostheses constituted by an animal or homologous tissue. In this sense, one sector that is representative is the cardiovascular sector, especially in terms of the social and health impact that the established practice of cardiac valve replacement can cause.
Biomedical technology is capable of developing and surgically applying valve prostheses for replacement that can imitate the opening and closing function of dysfunctional native valves. A
desirable bioprosthetic heart valve substitute (BHV) should be capable of allowing a trans-valve flow that can overlap that of the analogue original, healthy valve, to ensure a long lifetime and not generate haemolytic or thrombogenic effects.
The valve substitutes that are most often used are biological prostheses derived from xenogeneic tissues, in particular from pig valves or valves produced with the bovine, equine or porcine pericardium.
Such valve prostheses and substitutes suffer from many criticalities that severely imit their clinical application.
The international patent application WO 2017/093147 discloses a method for the inactivation of xenoantigens, and in particular of alpha-Gal, in biological tissues for the production of bioprostheses. Aspects relating to calcification are incidentally mentioned as proved by the absence of any experimental description supporting its effectiveness.
The US patent application US 2014/018909 discloses a method for preserving tissues intended for applications in the cardiovascular field, from the products of reactions that accumulate in patients with diabetes and, in particular, resulting from the oxidation of lipid components. These catabolic products are named as AGEs and are responsible for accelerating the degeneration mechanisms of bioprosthetic substitutes, such as vessels and heart valves, in diabetic patients.
The method is disclosed in connection with Pentagalfoylglucose ¨ PGG, only and it is performed on a collagen matrix obtained by decellularizing a porcine heart valve and an elastin matrix obtained by treating a previously decellularized porcine carotid artery with alkali.
The international patent application WO 01/21228 discloses the use of gallotanic acid to mitigate the calcification of biological or synthetic tissues that can be used for the production of head valve substitutes.
Summary of the invention The inventors of the present patent application have surprisingly found a method for increasing the biocompatibility of prostheses, particularly of cardiac prostheses. In particular, the increased biocompatibility comprises the increase in one or more of:
preventing the formation of calcified deposits, inactivating xenoantigens in biological matrices, preventing the thrombus formation in a biological matrix, preventing the lipid infiltration into a biological matrix, preventing the onset of inflammatory process mediated by the cellular component, prevents the biofouling processes on a biological matrix.
Brief description of the !mires Figure 1: results of the assays on the phenolic compound release.
Figure 2: results of the in-vitro calcification assays.
Figure 3: the valve placed in the custom-fabricated silicone holder.
2 Figure 4: MPD¨Qms profiles of the untreated (A) and FACTAlm treated (B) commercials BHVs; the data represents means t SD (number of cardiac cycles averaged, n=10).
Figure 5: mean EOA of the untreated (n=2) and FACTATM treated (n=3) valve groups at each flow conditions tested; data represents means SD. Asterisks indicate significance differences between treated and untreated group.
Figure 6: PPD ¨ QPEAK profiles of the untreated (A) and FACTATM treated (B) commercial BHVs. Data represents means SD (number of cardiac cycles averaged, n=10).
Figure 7: mean regurgitation of the untreated (n=2) and FACTA n" treated (n=3) valve groups at each flow conditions tested (meanstSD).
Figure 8: mean energy losses for the untreated (n=2) and FACTABA treated (n=3) valve groups at each flow conditions tested (mean SD).
Figure 9: mean biornechanical parameters tor the untreated (n=2) and FACTATM
treated (n=3) valve groups (means SD). A: Elastic phase slope; B: collagen Phase slope; C: Transition strain; D: Transition stress; E: Failure strain; F: Ultimate tensile strength.
Asterisks indicate a significant difference between the untreated and treated groups for the specific parameter indicated.
Figure 10: some of the most significant commercial BHVs explanted from swine after 1 month of follow-up. FACTAni treated BHVs (D, E, and F), untreated BHVs (B and C), non-implanted BHV (A).
Figure 11: macroscopic aspects of untreated commercial BHVs after 1 month of follow-up in a common swine model. It is evident the formation of blood clots (A) and of a fibrotic pannus affecting the cusps (A, C and D) and the suture ring of the prostheses (B).
Figure 12: Hematoxylin & Eosin staining of untreated commercial BHVs after 1 month of follow-up in swine. The black arrows (box A and E) highlight the presence of a dense and homogeneous fibrotic layer on and in the ventricular surface of the leaflets.
A foreign body reaction is present in the other side of the leaflets (box C and (3) with inflammatory cells penetration (box D
Figure 5: mean EOA of the untreated (n=2) and FACTATM treated (n=3) valve groups at each flow conditions tested; data represents means SD. Asterisks indicate significance differences between treated and untreated group.
Figure 6: PPD ¨ QPEAK profiles of the untreated (A) and FACTATM treated (B) commercial BHVs. Data represents means SD (number of cardiac cycles averaged, n=10).
Figure 7: mean regurgitation of the untreated (n=2) and FACTA n" treated (n=3) valve groups at each flow conditions tested (meanstSD).
Figure 8: mean energy losses for the untreated (n=2) and FACTABA treated (n=3) valve groups at each flow conditions tested (mean SD).
Figure 9: mean biornechanical parameters tor the untreated (n=2) and FACTATM
treated (n=3) valve groups (means SD). A: Elastic phase slope; B: collagen Phase slope; C: Transition strain; D: Transition stress; E: Failure strain; F: Ultimate tensile strength.
Asterisks indicate a significant difference between the untreated and treated groups for the specific parameter indicated.
Figure 10: some of the most significant commercial BHVs explanted from swine after 1 month of follow-up. FACTAni treated BHVs (D, E, and F), untreated BHVs (B and C), non-implanted BHV (A).
Figure 11: macroscopic aspects of untreated commercial BHVs after 1 month of follow-up in a common swine model. It is evident the formation of blood clots (A) and of a fibrotic pannus affecting the cusps (A, C and D) and the suture ring of the prostheses (B).
Figure 12: Hematoxylin & Eosin staining of untreated commercial BHVs after 1 month of follow-up in swine. The black arrows (box A and E) highlight the presence of a dense and homogeneous fibrotic layer on and in the ventricular surface of the leaflets.
A foreign body reaction is present in the other side of the leaflets (box C and (3) with inflammatory cells penetration (box D
3 and H). Box A and E magnification 4X. Box B, C F and G magnification 10X. Box D and H
magnification 40X.
Figure 13: Hematoxylin & Eosin staining of FACTAna treated commercial BHVs after 1 month follow-up in the swine. Where foreign body reaction occurs (box A), no cellular penetration is appreciable (box C). Box A D and F magnification 4X Box B, E and G
magnification 10X. Box C
magnification 40X.
Figure 14: Oil Red "0" staining for lipid identification. FACTAlm treated (E, F, G and H) and untreated (A, B, C and D) commercial BHVs after 1 month of follow-up in the swine. Red colour reveals the presence of lipid infitration. Box A, C, E and G magnification 4X.
Box B, D, F and H
magnification 1COC.
Figure 15: Von Kossa staining of untreated commercial BHVs after 1 month follow-up in the swine. Evident calcium deposition, especially at the level of the external interfaces of the leaflets, were reported. Wide spreads of microcalcifications affecting the internal portion of the stroma are visible. Box A, D and G magnification 4X. Box B, E and H
magnification 10X.
Figure 18: Von Kossa staining of FACTAlm treated commercial BHVs after 1 month follow-up in the swine. No calcium deposit was observable. Complete absence of micro-calcification. Box A, C and E magnification 4X. Box B, D and F magnification 10X;
Figure 17: Mallory Trichromic staining of untreated commercial BHVs after 1 month follow-up in the swine. The collagenic matrix is recognizable in blue colour, the presence of structured thrombi in red/yellow. Box A C, E and G magnification 4X. Box B, D, F and H
magnification 10X.
Figure 18: Mallory Trichromic staining of untreated commercial BHVs after 1 month of follow-up in the swine. In red/yellow colour is dearly evident the presence of a fibrous pannus that culminates in a thrombus in the ventricular surface of the leaflet. Box A, magnification 4X, multiple panel magnification 10X.
Figure 19: Mallory Trichromic staining of FACTATh treated commercial BHVs after 1 month follow-up in the swine. No significant presence of abnormal fibrous formation, like pannus or structured thrombi. In some samples is clearly evident the preservation of the elastic component
magnification 40X.
Figure 13: Hematoxylin & Eosin staining of FACTAna treated commercial BHVs after 1 month follow-up in the swine. Where foreign body reaction occurs (box A), no cellular penetration is appreciable (box C). Box A D and F magnification 4X Box B, E and G
magnification 10X. Box C
magnification 40X.
Figure 14: Oil Red "0" staining for lipid identification. FACTAlm treated (E, F, G and H) and untreated (A, B, C and D) commercial BHVs after 1 month of follow-up in the swine. Red colour reveals the presence of lipid infitration. Box A, C, E and G magnification 4X.
Box B, D, F and H
magnification 1COC.
Figure 15: Von Kossa staining of untreated commercial BHVs after 1 month follow-up in the swine. Evident calcium deposition, especially at the level of the external interfaces of the leaflets, were reported. Wide spreads of microcalcifications affecting the internal portion of the stroma are visible. Box A, D and G magnification 4X. Box B, E and H
magnification 10X.
Figure 18: Von Kossa staining of FACTAlm treated commercial BHVs after 1 month follow-up in the swine. No calcium deposit was observable. Complete absence of micro-calcification. Box A, C and E magnification 4X. Box B, D and F magnification 10X;
Figure 17: Mallory Trichromic staining of untreated commercial BHVs after 1 month follow-up in the swine. The collagenic matrix is recognizable in blue colour, the presence of structured thrombi in red/yellow. Box A C, E and G magnification 4X. Box B, D, F and H
magnification 10X.
Figure 18: Mallory Trichromic staining of untreated commercial BHVs after 1 month of follow-up in the swine. In red/yellow colour is dearly evident the presence of a fibrous pannus that culminates in a thrombus in the ventricular surface of the leaflet. Box A, magnification 4X, multiple panel magnification 10X.
Figure 19: Mallory Trichromic staining of FACTATh treated commercial BHVs after 1 month follow-up in the swine. No significant presence of abnormal fibrous formation, like pannus or structured thrombi. In some samples is clearly evident the preservation of the elastic component
4
5 (box E and F, G and H). Box A, C, E and G magnification 4X. Box B, 0, F and H
magnification 10X.
Figure 20: staining of the reference commercial BHV (not implanted in the swine). H&E box A and B; Oil Red 0", box C and D; Mallory Trichromic, box E and F; Von Kossa, box G and H. Box A, C, E and G magnification 4X. Box B, D, F and H magnification 10X
Figure 21: multiple staining of FACTAn' treated commercial BHVs after 1 month follow-up in the swine. H&E box A and B; Mallory Trichromic, box C and D; Oil Red "0", box E; Von Kassa, box F. Box A, C, E and F magnification 4X. Box B and D, magnification 40X.
Figure 22: shows the percentage of S. aureus adhesiveness on FACTAn treated commercial BHVs leaflets compared to untreated leaflets (n=5 for each type of samples).
Figure 23: results of the Ca 2+ quantification comparison (by ICP analysis) in FACTAlm treated (F) and untreated (C) leaflets from commercial bioprosthetic heart valve after 1, 2 and 4 months follow-up in the WT mice.
Figure 24: results of the Ca" " quantification after Von Kassa histological staining on FACTAn' treated (F) and not treated (C) samples analysis after 4 months follow-up in the WT
mice.
Figure 25: results of the Ca2+ quantification comparison (by ICP analysis) in FACTAlm treated (F) and untreated (C) leaflets from commercial bioprosthetic heart valve leaflets after 1 and 2 months of follow-up in alpha-Gal KO mice.
Object of the invention In a first object, the present invention discloses a method for preventing the formation of calcified deposits in a biological matrix.
In a preferred embodiment, said method comprises the step of contacting said biological matrix with a solution comprising a mixture of phenolic compounds for a period of fewer than two hours at the temperature of 35 2 C and in the dark.
According to an aspect of the invention, the method disclosed also inactivates xienoantigens in biological matrices.
According to another aspect of the invention, the method disclosed prevents the thrombus formation on a biological matrix.
According to a further aspect of the invention, the method disclosed prevents the lipid infiltration into a biological matrix.
According to a still further aspect of the invention, the method disclosed prevents the onset of an inflammatory process mediated by the cellular component According to another further aspect of the invention, the method disclosed prevents the formation of the microorganism biofilm on a biological matrix (biofouling).
In a preferred embodiment, the method disclosed provides one or more of:
preventing the formation of calcified deposits, inactivating xenoantigens in biological matrices, preventing the thrombus formation on a biological matrix, preventing the lipid infiltration into a biological matrix, preventing the onset of inflammatory process mediated by the cellular component prevents the biofouling processes on a biological matrix.
In a more preferred embodiment, the method disclosed provides for preventing the formation of calcified deposits, inactivating xenoantigens in biological matrixes, preventing the thrombus formation on a biological matrix, preventing the lipid infiltration into a biological matrix and preventing the onset of inflammatory process mediated by the cellular component, prevents the biofouling processes on a biological matrix.
A biological matrix obtained with the method of the invention is another object of the present application.
A biological matrix obtained with the method of the invention for use in the treatment of heart diseases in the medical, biomedical and/or veterinary field represents a second object of the present application.
In one aspect of the invention, it is disclosed a method for the treatment of heart diseases in humans or animals comprising the use of a biological matrix obtained according to the method of the invention.
magnification 10X.
Figure 20: staining of the reference commercial BHV (not implanted in the swine). H&E box A and B; Oil Red 0", box C and D; Mallory Trichromic, box E and F; Von Kossa, box G and H. Box A, C, E and G magnification 4X. Box B, D, F and H magnification 10X
Figure 21: multiple staining of FACTAn' treated commercial BHVs after 1 month follow-up in the swine. H&E box A and B; Mallory Trichromic, box C and D; Oil Red "0", box E; Von Kassa, box F. Box A, C, E and F magnification 4X. Box B and D, magnification 40X.
Figure 22: shows the percentage of S. aureus adhesiveness on FACTAn treated commercial BHVs leaflets compared to untreated leaflets (n=5 for each type of samples).
Figure 23: results of the Ca 2+ quantification comparison (by ICP analysis) in FACTAlm treated (F) and untreated (C) leaflets from commercial bioprosthetic heart valve after 1, 2 and 4 months follow-up in the WT mice.
Figure 24: results of the Ca" " quantification after Von Kassa histological staining on FACTAn' treated (F) and not treated (C) samples analysis after 4 months follow-up in the WT
mice.
Figure 25: results of the Ca2+ quantification comparison (by ICP analysis) in FACTAlm treated (F) and untreated (C) leaflets from commercial bioprosthetic heart valve leaflets after 1 and 2 months of follow-up in alpha-Gal KO mice.
Object of the invention In a first object, the present invention discloses a method for preventing the formation of calcified deposits in a biological matrix.
In a preferred embodiment, said method comprises the step of contacting said biological matrix with a solution comprising a mixture of phenolic compounds for a period of fewer than two hours at the temperature of 35 2 C and in the dark.
According to an aspect of the invention, the method disclosed also inactivates xienoantigens in biological matrices.
According to another aspect of the invention, the method disclosed prevents the thrombus formation on a biological matrix.
According to a further aspect of the invention, the method disclosed prevents the lipid infiltration into a biological matrix.
According to a still further aspect of the invention, the method disclosed prevents the onset of an inflammatory process mediated by the cellular component According to another further aspect of the invention, the method disclosed prevents the formation of the microorganism biofilm on a biological matrix (biofouling).
In a preferred embodiment, the method disclosed provides one or more of:
preventing the formation of calcified deposits, inactivating xenoantigens in biological matrices, preventing the thrombus formation on a biological matrix, preventing the lipid infiltration into a biological matrix, preventing the onset of inflammatory process mediated by the cellular component prevents the biofouling processes on a biological matrix.
In a more preferred embodiment, the method disclosed provides for preventing the formation of calcified deposits, inactivating xenoantigens in biological matrixes, preventing the thrombus formation on a biological matrix, preventing the lipid infiltration into a biological matrix and preventing the onset of inflammatory process mediated by the cellular component, prevents the biofouling processes on a biological matrix.
A biological matrix obtained with the method of the invention is another object of the present application.
A biological matrix obtained with the method of the invention for use in the treatment of heart diseases in the medical, biomedical and/or veterinary field represents a second object of the present application.
In one aspect of the invention, it is disclosed a method for the treatment of heart diseases in humans or animals comprising the use of a biological matrix obtained according to the method of the invention.
6 A solution comprising a phenolic compound or a mixture of phenolic compounds to be used in the methods of the present patent application represents a further object of the invention.
According to another aspect of the invention, it is disdosed a method for the preparation of the invention solution comprising a mixture of phenolic compounds.
In a further object, the present invention discloses a kit for performing the invention method.
Detailed description of the invention According to a first object, the present invention discloses a method for preventing the formation of calcified deposits in a biological matrix.
For the purposes of the present invention, a calcification may occur on the surface of a biological matrix or inside a biological matrix.
For the purposes of the present description, a method according to the invention is referred to as FACTATM.
In particular, said method comprises the step of contacting the said biological matrix with a solution comprising a mixture of phenolic compounds.
For the purposes of the present invention, biological matrices are xenomatrices, i.e. they are not of human origin.
In particular, they can have equine, porcine or bovine origin.
In a preferred embodiment, biological matrices shall be intended as: vessels, cardiac valves, tendons, ligaments, pericardium, muscular fasciae, dura meter, tympanic membrane, intestinal submucosa, cartilages, adipose tissue and bone tissue, pelvic, abdominal and breast tissue.
In a more preferred embodiments, biological matrices are selected in the group comprising cardiovascular prostheses (cardiac valves) and pericardial tissue patches.
An example of such cardiac valve is represented by Trffectan" Valve with Glideim Technology and Epicul Mitre! Valve (Abbott(St. Jude Medical, St. Paul, MN, USA).
Other examples for mere explanatory purposes may be Sapien 3, Sapien 3 Ultra and Sapien XT transcatheter heart valve (Edwards Lifesciences, Irvine, CA, USA), Inspiris Resilia,
According to another aspect of the invention, it is disdosed a method for the preparation of the invention solution comprising a mixture of phenolic compounds.
In a further object, the present invention discloses a kit for performing the invention method.
Detailed description of the invention According to a first object, the present invention discloses a method for preventing the formation of calcified deposits in a biological matrix.
For the purposes of the present invention, a calcification may occur on the surface of a biological matrix or inside a biological matrix.
For the purposes of the present description, a method according to the invention is referred to as FACTATM.
In particular, said method comprises the step of contacting the said biological matrix with a solution comprising a mixture of phenolic compounds.
For the purposes of the present invention, biological matrices are xenomatrices, i.e. they are not of human origin.
In particular, they can have equine, porcine or bovine origin.
In a preferred embodiment, biological matrices shall be intended as: vessels, cardiac valves, tendons, ligaments, pericardium, muscular fasciae, dura meter, tympanic membrane, intestinal submucosa, cartilages, adipose tissue and bone tissue, pelvic, abdominal and breast tissue.
In a more preferred embodiments, biological matrices are selected in the group comprising cardiovascular prostheses (cardiac valves) and pericardial tissue patches.
An example of such cardiac valve is represented by Trffectan" Valve with Glideim Technology and Epicul Mitre! Valve (Abbott(St. Jude Medical, St. Paul, MN, USA).
Other examples for mere explanatory purposes may be Sapien 3, Sapien 3 Ultra and Sapien XT transcatheter heart valve (Edwards Lifesciences, Irvine, CA, USA), Inspiris Resilia,
7 Intuity Valve System, Magna Easy, Perimount RSR and Perimount Valve (Edwards Lifesciences, Irvine, CA, USA), Avalusm, Contegra Valved Conduit, Freestyle)", Hancock II
Mosaic"' and Mosaic"' Ultra, Melody"' and CoreValve transcatheter valve replacement platform (Medtronic, Minneapolis, MN, USA), Acurate Neon' and Lotu Edge"' Aortic Valve System (Boston Scientific, Marlborough, MA, USA), Accede) Transapical Mitral Valve (Sinomed, Tianjin, China), XinliOD
(KingstronBio, Jiangsu, China), Bioconduirm, Biomitralp", Biopulmonic""
Conduit and Injectable Biopulmoniclu (Biolntegral, Mississauga, ON, Canada).
In a still preferred embodiment, the cardiac valves which can be treated according to the present invention are represented by trans-catheter implantable head valves (TAVI); said valves require to be implanted through a catheter and, accordingly, need to be pliable to be housed within the catheter.
For the purposes of the present invention, a phenolic compound within the phenolic compound mixture above referred shall be intended as a phenolic or polyphenolic compound (in some instances used here as synonyms) selected from the group comprising:
simple phenols, phenolic aldehydes, phenolic acids, phenylamines, phenol compounds, flavonoids, phenylpropanoids and tannins.
In particular, a phenolic compound is selected in the group comprising:
vanillin, cinnamic acids, phenylalanine, coumarins, xanthones, catechins, flavononids, flavones, chalcones, flavanonols, flavanols, leucoanthocyanidin, anthocyanidin, hydroxycinnamic acids, phenylpropanoids.
More in particular, a phenolic compound can be selected in the group comprising:
resveratrol, aloin, cyanarin, epigallocatechin, tannic acid, caffeic acid, chlorogenic acid, hydroxytyrosol, rosmarinic acid, narigenin, gallic acid, hesperidin, quinic acid, eleonolic acid, pinoresinol, luteolin, apigenin, tangeritin, isorhamnetin, Icaempferol, myricetin, eriodictyol, hesperetin, naringenin, theaflavin, thearubigins, daidzein, genistein, glycitein, pterostilbene, delphinidin, malvidin, pelargonidin, peonidin, chicoric acid, ferulic acid, salicylic acid.
As per one embodiment of the present invention, curcumin can also be used.
Mosaic"' and Mosaic"' Ultra, Melody"' and CoreValve transcatheter valve replacement platform (Medtronic, Minneapolis, MN, USA), Acurate Neon' and Lotu Edge"' Aortic Valve System (Boston Scientific, Marlborough, MA, USA), Accede) Transapical Mitral Valve (Sinomed, Tianjin, China), XinliOD
(KingstronBio, Jiangsu, China), Bioconduirm, Biomitralp", Biopulmonic""
Conduit and Injectable Biopulmoniclu (Biolntegral, Mississauga, ON, Canada).
In a still preferred embodiment, the cardiac valves which can be treated according to the present invention are represented by trans-catheter implantable head valves (TAVI); said valves require to be implanted through a catheter and, accordingly, need to be pliable to be housed within the catheter.
For the purposes of the present invention, a phenolic compound within the phenolic compound mixture above referred shall be intended as a phenolic or polyphenolic compound (in some instances used here as synonyms) selected from the group comprising:
simple phenols, phenolic aldehydes, phenolic acids, phenylamines, phenol compounds, flavonoids, phenylpropanoids and tannins.
In particular, a phenolic compound is selected in the group comprising:
vanillin, cinnamic acids, phenylalanine, coumarins, xanthones, catechins, flavononids, flavones, chalcones, flavanonols, flavanols, leucoanthocyanidin, anthocyanidin, hydroxycinnamic acids, phenylpropanoids.
More in particular, a phenolic compound can be selected in the group comprising:
resveratrol, aloin, cyanarin, epigallocatechin, tannic acid, caffeic acid, chlorogenic acid, hydroxytyrosol, rosmarinic acid, narigenin, gallic acid, hesperidin, quinic acid, eleonolic acid, pinoresinol, luteolin, apigenin, tangeritin, isorhamnetin, Icaempferol, myricetin, eriodictyol, hesperetin, naringenin, theaflavin, thearubigins, daidzein, genistein, glycitein, pterostilbene, delphinidin, malvidin, pelargonidin, peonidin, chicoric acid, ferulic acid, salicylic acid.
As per one embodiment of the present invention, curcumin can also be used.
8 For the purposes of the present invention, derivatives of the above disclosed phenolic or polyphenolic compound are also encompassed; for instance, salts or esters may also be used.
In one embodiment of the invention, the solution comprises a mixture of two or more of the above disclosed phenylpropanoids.
Within the solution of the invention, each phenylpropanold may be present in a concentration comprised between about 0.2-5 mg/ml * 0.5 mg/ml (w/total volume of the solution).
Here below there are reported some solutions according to the above disclosure:
Solution Compound ¨ quantity (mg1m1) Compound ¨ quantity (mg/m1) 0.5 mg/ml *0.5 mg/m1 A Resveratrol 3 mg/ml Aloin 1.5 mg/ml Resveratrol 3 mg/ml Cynarin 2 mg/ml Epigallocatechin 2 mg/m1 Aloin 1.5 mg/ml Tannic Acid 4 mg/ml Chlorogenic Acid 4 mg/m1 Tannic Acid 4 mg/ml Caffeic Acid 2 mg/ml Chlorogenic Acid 4 mg/ml Hydroxytyrosol 4 mg/m1 Rosmarinic Acid 2.5 mg/m1 Aloin 1.5 mg/m1 Naringenin 1 mg/ml Gallic Acid 1.5 mg/ml Hesperetin 2 mg/m1 Gallic Acid 1.5 mg/m1 In particular, in the method of the invention the step of contacting is performed for a period of time of less than 2 hours.
Preferably, the step of contacting is performed for a period of about one hour.
In a preferred embodiment of the invention, the contacting step is continued for a period of about 30 minutes.
In a more preferred embodiment, a lust contacting step is repeated for one additional 30-minute period.
Optionally, between the two contacting steps, a rinsing step may be performed.
In one embodiment of the invention, the solution comprises a mixture of two or more of the above disclosed phenylpropanoids.
Within the solution of the invention, each phenylpropanold may be present in a concentration comprised between about 0.2-5 mg/ml * 0.5 mg/ml (w/total volume of the solution).
Here below there are reported some solutions according to the above disclosure:
Solution Compound ¨ quantity (mg1m1) Compound ¨ quantity (mg/m1) 0.5 mg/ml *0.5 mg/m1 A Resveratrol 3 mg/ml Aloin 1.5 mg/ml Resveratrol 3 mg/ml Cynarin 2 mg/ml Epigallocatechin 2 mg/m1 Aloin 1.5 mg/ml Tannic Acid 4 mg/ml Chlorogenic Acid 4 mg/m1 Tannic Acid 4 mg/ml Caffeic Acid 2 mg/ml Chlorogenic Acid 4 mg/ml Hydroxytyrosol 4 mg/m1 Rosmarinic Acid 2.5 mg/m1 Aloin 1.5 mg/m1 Naringenin 1 mg/ml Gallic Acid 1.5 mg/ml Hesperetin 2 mg/m1 Gallic Acid 1.5 mg/m1 In particular, in the method of the invention the step of contacting is performed for a period of time of less than 2 hours.
Preferably, the step of contacting is performed for a period of about one hour.
In a preferred embodiment of the invention, the contacting step is continued for a period of about 30 minutes.
In a more preferred embodiment, a lust contacting step is repeated for one additional 30-minute period.
Optionally, between the two contacting steps, a rinsing step may be performed.
9 According to a preferred embodiment of the invention, the method is performed completely in the dark, is. avoiding any exposure to light.
As per the temperature of the contacting step, it is preferably performed at the temperature of about +35 C 2 C.
In a preferred embodiment of the invention, after the contacting step, the matrix may be subjected to one or more washing steps.
Preferably, said washing step is performed with a suitable buffer; for example, a suitable buffer may be represented by phosphate buffer.
Each washing step may be performed for a period of about 15 minutes.
According to one embodiment of the invention, the method can be performed on both native biological matrix and biological matrix that had previously been treated for other purposes, for instance for stabilizing the protein, lipid and cell structures as well as lowering the potential antigenic action of the host.
For the purposes of the present invention, biological matrices may comprise:
decellularized extracellular matrix, partially digested matrix and gelatins from animal origin.
For instance, before treating the biological matrix according to the method of the invention, it can be subjected to a treatment with glutaraldehyde, formaldehyde and quercefin.
According to an aspect of the invention, the method disclosed also inactivates xenoantigens in biological matrices.
With the term axenoantigen" it is intended of animal origin that can be recognized by the immune system and can induce an antibody/immune-mediated/inflammatory response in the human host organism; in the present description the terms "xenoantigen", "antigen", "xenogeneic antigen", "epitope" and "crucial antigen" can have the same meaning, and can be used together or to substitute for each other.
For the purposes of the present invention, "xenoantigen" refers to the alpha-Gal epitope.
According to another aspect of the invention, the method disclosed prevents the thrombus formation and clots on and in a biological matrix.
According to a further aspect of the invention, the method disclosed prevents the lipid infiltration into a biological matrix.
According to a still further aspect of the invention, the method disclosed prevents the onset of an inflammatory process mediated by the cellular component According to another further aspect of the invention, the method disclosed prevents the formation of the microorganism biofilm on a biological matrix (biofouling).
In particular, the method of the invention has proved to prevent the formation of a biofilm formed by Staphylococcus aureus by decreasing the adhesive capacity on the prostheses surface.
The method of the invention is effective on both Gram' and Gram. bacteria_ A biological matrix obtained with the method of the invention is another object of the present application.
In particular, said biological matrix is represented by a cardiovascular bio-prostheses obtained with the method disclosed, which has a significant decrease in the formation of calcific deposits, structured thrombus, lipoproteins infiltration and significant resistance to bacterial adhesion and consequent tissue colonization.
According to a second object, the present invention discloses the biological matrix obtained with the method above described for use in the treatment of heart diseases in the medical or in the veterinary field.
As a further object of the present invention, it is disclosed a solution comprising a mixture of phenolic compounds to be used in the method of the present patent application.
In particular, said solution is prepared by mixing two or more phenolic compounds as above disclosed.
More in detal said solution might be prepared in a suitable buffer.
For example, a sodium phosphate buffer can be used.
Alternatively, the mixture of phenolic compounds may be prepared in a solution of NaOH.
The solution of the invention may be added with a suitable enzyme endowed with oxidase activity; for instance, there can be used tyrosinase, L-gulonolactone oxidase, laccase, etc.
The solution is preferably prepared in the dark, i.e. avoiding any exposure to light.
According to a third object of the invention, it is disclosed a kit for performing the above disclosed method.
In particular, said kit comprises:
- a container containing a suitable buffer, - a container holding an adequate quantity of a mixture of phenolic compounds to be dissolved, - one or more containers holding the washing buffers;
- an instruction booklet containing the description of the timings and modes of application of the procedure.
In an aspect of the invention, the phenolic compounds may be present in powder form to be dissolved in the buffer.
The present invention will be further described in connection with the following experimental section.
Experimental section In the following Experimental section, the term "knockout animal for the alpha-Gal antigen" refers to an animal in which the gene that encodes for the alpha-galactosyltransferase enzyme has been silenced. Such enzyme is responsible for attacking the membrane glycoproteins and lipoproteins of the alpha-Gal epitope. Its absence causes the production of tissues that lack the epttope in question entirely and which in this respect are entirely comparable to the tissue of the human body.
In the present invention, knockout animal vascular tissues for the alpha-Gal antigen were used as absolute negative control.
Xenoantioen inactivation Commercial Trifecta Wm' bioprosthetic aortic heart valves were extracted from their packaging and subjected to two washing steps in phosphate buffer for 15 minutes each.
Different solutions were prepared based on the phenolic mixtures reported above and filtered with a 0.2 pm sterile membrane. The Tiffecta Grim valves were incubated with each single solution under moderate but constant stirring in the dark, for two step of 25 5 minutes each, at room temperature.
At the end of the incubation, the treated bioprosthetic heart valves were washed twice in phosphate buffer for 15 minutes each.
A set of original Trifecta Grn" valves were adopted untreated off-the-shelves as control.
The assessment of the presence of any epitopes still active on the surface of the treated samples is based on a modification of the illustrated method by the inventors and described in the Italian patent no. 0001409783 and in EP 2.626.701.
Briefly, tissue samples from the treated and untreated TrifectaIN valves were placed in test tubes to which a phosphate buffer is added up to a final volume comprised between 1000 pL and 1500 pL
Then, a monoclonal mouse antibody, directed against the alpha-Gal epitope, is added (in the present example this is an IgM clone called M86), at the preferable concentration of [1:50] v/v and the whole is incubated for 120-110 minutes at 37 2 C under constant but moderate stirring.
At the end, the samples were subjected to centrifugation at 14,750 x g for 301:5 minutes at ambient temperature.
During the incubation with the M86 antibody, a 96-well plate was prepared, in which the bottom of the wells is lined with 100 pL per cell of alpha-Gal/serum albumin at 5 pg/ml in phosphate buffer.
The plate thus prepared was incubated for 60-110 minutes at a temperature comprised between 30 C and 40 C, although it is preferable to stabilize everything at 37 C.
Then 3 washes were performed with 300 pL per well with a phosphate buffer at ambient temperature. The first washing was left to act for 5 minutes, and the two subsequent washes for 3 minutes.
The blocking was done with 300 pL per well with serum albumin, followed by incubation for 60 10 minutes at ambient temperature, in darkness. Subsequently, 3 washes as above were performed.
For each well, 100 pi_ of supernatant, taken after centrifugation from each treated sample, was added.
The samples were loaded into the plate, each type of sample occupying the wells of an entire column. There follows incubation of the plate for 120 10 minutes at a temperature comprised between 30 C and 40 C, although it is preferable to stabilize everything at 37 C.
Then 3 washes as above were performed, and 100 p1 per well is added of a solution of secondary antibody (rabbit polyclonal anti-mouse) conjugated with peroxidase enzyme (the ideal solutions of such antibody have been found to be [1:1000], [1:500] and [1:100], preferably the intermediate one [1:500] was adopted).
The plate is then incubated again for 80 10 minutes at a temperature comprised between 30 C
and 40 C, although it is preferable to stabilize everything at 37 C.
Then 3 washes as above were performed. 100 pi_ is added per well of a development solution for the peroxidase enzyme, followed by incubation of the plate for 5 1 minute in darkness_ Subsequently, 50 pi_ was added per well of a stop solution constituted by H2504 2M, and the plate is then read in a plate reader at 450 nm.
An overall analysis of the various adopted polyphenol mixtures shows that it is possible to obtain an inactivation of the alpha-Gal antigen in the treated Trifectan" valves between 80 2% and 95 0.8% compared to the untreated samples.
The same type of valve, treated and non-treated has been subjected to the following in-vitro and in-vivo analysis.
In particular, the treatment has been performed with a solution according to the present invention.
Evaluation of FACTATM treatment stability in time The FACTATm treatment is based on the action of a mixture containing specific polyphenols according to the present invention. However, polyphenols at certain dosages can be toxic (LD50 5 g/kg), accumulating in the liver and kidneys. To confirm the stability of the FACTAlm treatment, we evaluated the release of phenolic residues over time. After FACTATIA
treatment, commercial BHVs leaflets were left in the storage solution as supplied by the manufacturer. At different time-point of 7 and 14 days and 1, 3 and 9 months, the amount of phenolic compounds released from the tissue was determined (n=9 samples for each time point). As a control, a set of untreated commercial BHV leaflets were analyzed at same time-point. The total polyphenol content present in the solutions was evaluated using a protocol based on the reaction, under conditions of alkaline pH, between the phenolic compounds eventually present in the storage solution and diazonium salts.
The reaction product is a stable chromophore that can be detected and quantified by absorbance analysis at a wavelength of 480 nm. The concentration of phenols present in the sample is quantified by an external calibration method with a catechin standard and is therefore expressed as a milirnolar concentration of catechin equivalent (mM).
The results are shown in Figure 1.
Totally, 160 ppm of phenolic compounds were released from a treated tissue in 9 months. The release occurs almost in the first 14 days after the treatment Concerning the toxic potential, it can be confined that the total amount of polyphenols leakage from the treated tissues does not result in any health risk in fact, it is lower than the concentration of polyphenols present in the human plasma following the uptake with the diet.
In-vitro calcification assay Leaflets from untreated (B) and FACTATh' treated (BT) commercial BHVs, native (WT) and FACTATN treated native aortic porcine leaflets (WT T) and alpha-Gal knockout porcine aortic leaflets (KO) were incubated in pooled normal human serum (Innovative Research, Peary Court Novi, MI) with 2% of penicillin and streptomycin for 14 days at arc. As a control, a set of samples was incubated in PBS in the same condition. After incubation, samples were washed twice in PBS
for 10 min and subjected to acid hydrolysis in HNO3 at 110 C for 12 h. Calcium evaluation was performed in hydrolyzed samples by inductively coupled plasma according to the directives of the EPA8010D method and expressed as pg Ca241mg of dry defatted weight (d.d.w.).
The results are reported in Figure 2.
FACTAlm treated BEN (BT) shows a decrease in the calcffic propensity of 90% (B
vs BT p<0.05) and of 44.4% (BT vs KO, p<0.05) when compared with untreated BHVs (B) and alpha-Gal knockout tissues (KO) respectively. Knockout tissue is considered the least calcifying biological support and is used as an absolute negative control in xenotransplant-induced calcification studies.
FACTADA treated BHV has been shown to calcify almost 50% less than the KO
standard. If the FACTAT" method is applied to a native tissue (WT T, not fixed with glutaraldehyde), the anti-calcifying effectiveness compared to the reference tissue KO rise to 85% (WT T
vs KO p<0.05).
Hydrodynamic Assessment The hydrodynamic performance of the valves was assessed under simulated pulsatile flow in a Vniitro Pulse Duplicator System (Vivito Labs Inc., Victoria, BC, Canada). The flow simulator was used to model the left side of the heart. The test valves were fitted into a custom-fabricated silicon holder (Figure3) and placed in the aortic position of the pulsatile flow system. A 25 mm Bjork-Shiley tilting disc valve was used in the mitral position as a reference valve. The testing was performed in 0.9% (w/v) NaCI at room temperature. The valves were tested under five pulsatile flow conditions (Table 1), according to ISO 5840-3. The flow conditions corresponded to cardiac outputs between 2.5-9 1/min. During testing, the diastolic/systolic pressure was set to 80/120 mm Hg, whereas the systolic duration occupied 35% of the cardiac cycle. At each flow condition the valves were preconditioned for 5 min, before the pressure and flow signals were recorded over 10 cycles at each flow condition for each valve group (FACTA"' treated BHVs, n=3;
untreated BHVs, n=2).
Flow condition Cycle rate Stroke volume (bpm) (ml) Table I ¨ Pulsatile flow conditions used in the hydrodynamic assessment.
The hydrodynamic performance of the valves was assessed in terms of the mean pressure drop (MPD) and peak pressure drop (PPD) across the valve, root mean square forward flow through the valve (QpiAs), peak forward flow through the valve (QPEAK), valve effective orifice area (EOA), reverse flow through the valve during valve closure and while the valve was fully closed, and valve energy losses. As defined in ISO 5840-3, the EOA was measured using only the volumetric flow rate and the pressure difference across the valve during the positive pressure interval of the forward flow phase. The results tor each test were averaged over the number of cycles recorded (n=10). The data was analyzed in Microsoft Excel and Prism 7 for Windows (v7.03, GraphPad Software Inc., California) and expressed as mean standard deviation (SD).
Two-sided unpaired !-test was used to assess significant differences between the treated and untreated groups, at the 0.05 confidence levels.
The MPD ¨ Qs profiles of the untreated and treated valves, averaged over 10 cycles at each flow condition, are illustrated in Figure 4A and 4B, respectively. Both valve groups demonstrated excellent repeatability and similar ORM - PD profiles between them.
The mean E0As of the treated and untreated valves calculated for each flow condition is illustrated in Figure 5. There was no statistically significant difference in EOA between the untreated and treated group, apart from flow condition 100/80 (bpm/sv), at which the treated group demonstrated a significantly smaller (p<0.05) EOA compared to the untreated one.
The PPD-QpEAK profiles of the untreated and treated valves, averaged over 10 cycles at each condition, are illustrated in Figure 6A and 6B, respectively. Both groups demonstrated similar PPD-QpEasx profiles.
The mean dynamic and static regurgitation volumes of the untreated and treated groups at each flow conditions are illustrated in Figure 7. The dynamic regurgitation (dosing volume) and static regurgitation (closed volume) for both groups were negative representing back-flow through the valves. In general, the regurgitation volumes were more significant for the lower flow conditions and increased with increasing flow rates. No statistically significant differences were found in the regurgitation volumes between the untreated and treated groups.
The mean energy losses for the treated and untreated groups are illustrated in Figure 8. With increasing flow condition, an opposite pattern was observed for the energy losses in the forward flow and closed phase. The lowest energy loss during the forward flow phase was observed for the low-flow condition (60/60) and, increased with increasing flow rates. In contrast, the highest energy loss during the dosed phase was observed for the low-flow condition and decreased with increasing flow rates. There was no significant difference in the energy losses between the untreated and treated groups, in any of the flow conditions tested.
Biomechanical Assessment Low-strain rate uniaxial tensie loading to failure was carried in a Instron tensile tester (5967 Dual Column Series) with a 100N load cell. One leaflet was excised from each valve and used to isolate a specimen with test dimensions 6x3 min (length x width). The thickness of the samples was measured at 3 points along their length, using a Mitutoyo thickness gauge and averaged. During testing, each sample was preloaded to 0.01 N, at a strain rate of 20 mm/min, and then loaded to failure at the same rate. The recorded load-extension response of each sample was converted to engineering stress-engineering strain. The stress-strain curves were used to calculate the elastic and collagen phase slopes, transition stress and strain, failure strain and ultimate tensile strength.
The data was analysed in Excel and expressed as mean SD. Two-sided unpaired t-test was used to assess significant differences between the treated and untreated groups at the 0.05 confidence level.
The mean biomechanical parameters of the FACTATh treated and untreated groups are shown in Figure 9. Significant differences between the treated and untreated groups were found in the case of the failure strain (p<0.05). No significant differences were found in any of the other parameters between the FACTAlm treated and untreated groups. Although no statistical significance was found in the case of the elastic phase slope (Figure 9A) and transition strain (Figure 9C) between the two groups, these parameters were shown to be increased (elastin phase slope) or decreased (transition strain) for the treated group compared to the untreated one. A
higher elastic phase and a lower transition strain would indicate a stiffer and less extensible material, respectively, under low strain.
In-vivo investigation on swine animal model FACTAns treated (n=5) and untreated (n=3) commercial Trifecta GT BHVs (St.Jude Medical, USA) were implanted in puknonary position in a pig animal model. After 1 month of follow-up, the BHVs were removed for investigation. Explanted BHVs were washed with two 15-minute steps in sterile PBS at 4 C and immediately photographed for macroscopic evaluation (Figure
As per the temperature of the contacting step, it is preferably performed at the temperature of about +35 C 2 C.
In a preferred embodiment of the invention, after the contacting step, the matrix may be subjected to one or more washing steps.
Preferably, said washing step is performed with a suitable buffer; for example, a suitable buffer may be represented by phosphate buffer.
Each washing step may be performed for a period of about 15 minutes.
According to one embodiment of the invention, the method can be performed on both native biological matrix and biological matrix that had previously been treated for other purposes, for instance for stabilizing the protein, lipid and cell structures as well as lowering the potential antigenic action of the host.
For the purposes of the present invention, biological matrices may comprise:
decellularized extracellular matrix, partially digested matrix and gelatins from animal origin.
For instance, before treating the biological matrix according to the method of the invention, it can be subjected to a treatment with glutaraldehyde, formaldehyde and quercefin.
According to an aspect of the invention, the method disclosed also inactivates xenoantigens in biological matrices.
With the term axenoantigen" it is intended of animal origin that can be recognized by the immune system and can induce an antibody/immune-mediated/inflammatory response in the human host organism; in the present description the terms "xenoantigen", "antigen", "xenogeneic antigen", "epitope" and "crucial antigen" can have the same meaning, and can be used together or to substitute for each other.
For the purposes of the present invention, "xenoantigen" refers to the alpha-Gal epitope.
According to another aspect of the invention, the method disclosed prevents the thrombus formation and clots on and in a biological matrix.
According to a further aspect of the invention, the method disclosed prevents the lipid infiltration into a biological matrix.
According to a still further aspect of the invention, the method disclosed prevents the onset of an inflammatory process mediated by the cellular component According to another further aspect of the invention, the method disclosed prevents the formation of the microorganism biofilm on a biological matrix (biofouling).
In particular, the method of the invention has proved to prevent the formation of a biofilm formed by Staphylococcus aureus by decreasing the adhesive capacity on the prostheses surface.
The method of the invention is effective on both Gram' and Gram. bacteria_ A biological matrix obtained with the method of the invention is another object of the present application.
In particular, said biological matrix is represented by a cardiovascular bio-prostheses obtained with the method disclosed, which has a significant decrease in the formation of calcific deposits, structured thrombus, lipoproteins infiltration and significant resistance to bacterial adhesion and consequent tissue colonization.
According to a second object, the present invention discloses the biological matrix obtained with the method above described for use in the treatment of heart diseases in the medical or in the veterinary field.
As a further object of the present invention, it is disclosed a solution comprising a mixture of phenolic compounds to be used in the method of the present patent application.
In particular, said solution is prepared by mixing two or more phenolic compounds as above disclosed.
More in detal said solution might be prepared in a suitable buffer.
For example, a sodium phosphate buffer can be used.
Alternatively, the mixture of phenolic compounds may be prepared in a solution of NaOH.
The solution of the invention may be added with a suitable enzyme endowed with oxidase activity; for instance, there can be used tyrosinase, L-gulonolactone oxidase, laccase, etc.
The solution is preferably prepared in the dark, i.e. avoiding any exposure to light.
According to a third object of the invention, it is disclosed a kit for performing the above disclosed method.
In particular, said kit comprises:
- a container containing a suitable buffer, - a container holding an adequate quantity of a mixture of phenolic compounds to be dissolved, - one or more containers holding the washing buffers;
- an instruction booklet containing the description of the timings and modes of application of the procedure.
In an aspect of the invention, the phenolic compounds may be present in powder form to be dissolved in the buffer.
The present invention will be further described in connection with the following experimental section.
Experimental section In the following Experimental section, the term "knockout animal for the alpha-Gal antigen" refers to an animal in which the gene that encodes for the alpha-galactosyltransferase enzyme has been silenced. Such enzyme is responsible for attacking the membrane glycoproteins and lipoproteins of the alpha-Gal epitope. Its absence causes the production of tissues that lack the epttope in question entirely and which in this respect are entirely comparable to the tissue of the human body.
In the present invention, knockout animal vascular tissues for the alpha-Gal antigen were used as absolute negative control.
Xenoantioen inactivation Commercial Trifecta Wm' bioprosthetic aortic heart valves were extracted from their packaging and subjected to two washing steps in phosphate buffer for 15 minutes each.
Different solutions were prepared based on the phenolic mixtures reported above and filtered with a 0.2 pm sterile membrane. The Tiffecta Grim valves were incubated with each single solution under moderate but constant stirring in the dark, for two step of 25 5 minutes each, at room temperature.
At the end of the incubation, the treated bioprosthetic heart valves were washed twice in phosphate buffer for 15 minutes each.
A set of original Trifecta Grn" valves were adopted untreated off-the-shelves as control.
The assessment of the presence of any epitopes still active on the surface of the treated samples is based on a modification of the illustrated method by the inventors and described in the Italian patent no. 0001409783 and in EP 2.626.701.
Briefly, tissue samples from the treated and untreated TrifectaIN valves were placed in test tubes to which a phosphate buffer is added up to a final volume comprised between 1000 pL and 1500 pL
Then, a monoclonal mouse antibody, directed against the alpha-Gal epitope, is added (in the present example this is an IgM clone called M86), at the preferable concentration of [1:50] v/v and the whole is incubated for 120-110 minutes at 37 2 C under constant but moderate stirring.
At the end, the samples were subjected to centrifugation at 14,750 x g for 301:5 minutes at ambient temperature.
During the incubation with the M86 antibody, a 96-well plate was prepared, in which the bottom of the wells is lined with 100 pL per cell of alpha-Gal/serum albumin at 5 pg/ml in phosphate buffer.
The plate thus prepared was incubated for 60-110 minutes at a temperature comprised between 30 C and 40 C, although it is preferable to stabilize everything at 37 C.
Then 3 washes were performed with 300 pL per well with a phosphate buffer at ambient temperature. The first washing was left to act for 5 minutes, and the two subsequent washes for 3 minutes.
The blocking was done with 300 pL per well with serum albumin, followed by incubation for 60 10 minutes at ambient temperature, in darkness. Subsequently, 3 washes as above were performed.
For each well, 100 pi_ of supernatant, taken after centrifugation from each treated sample, was added.
The samples were loaded into the plate, each type of sample occupying the wells of an entire column. There follows incubation of the plate for 120 10 minutes at a temperature comprised between 30 C and 40 C, although it is preferable to stabilize everything at 37 C.
Then 3 washes as above were performed, and 100 p1 per well is added of a solution of secondary antibody (rabbit polyclonal anti-mouse) conjugated with peroxidase enzyme (the ideal solutions of such antibody have been found to be [1:1000], [1:500] and [1:100], preferably the intermediate one [1:500] was adopted).
The plate is then incubated again for 80 10 minutes at a temperature comprised between 30 C
and 40 C, although it is preferable to stabilize everything at 37 C.
Then 3 washes as above were performed. 100 pi_ is added per well of a development solution for the peroxidase enzyme, followed by incubation of the plate for 5 1 minute in darkness_ Subsequently, 50 pi_ was added per well of a stop solution constituted by H2504 2M, and the plate is then read in a plate reader at 450 nm.
An overall analysis of the various adopted polyphenol mixtures shows that it is possible to obtain an inactivation of the alpha-Gal antigen in the treated Trifectan" valves between 80 2% and 95 0.8% compared to the untreated samples.
The same type of valve, treated and non-treated has been subjected to the following in-vitro and in-vivo analysis.
In particular, the treatment has been performed with a solution according to the present invention.
Evaluation of FACTATM treatment stability in time The FACTATm treatment is based on the action of a mixture containing specific polyphenols according to the present invention. However, polyphenols at certain dosages can be toxic (LD50 5 g/kg), accumulating in the liver and kidneys. To confirm the stability of the FACTAlm treatment, we evaluated the release of phenolic residues over time. After FACTATIA
treatment, commercial BHVs leaflets were left in the storage solution as supplied by the manufacturer. At different time-point of 7 and 14 days and 1, 3 and 9 months, the amount of phenolic compounds released from the tissue was determined (n=9 samples for each time point). As a control, a set of untreated commercial BHV leaflets were analyzed at same time-point. The total polyphenol content present in the solutions was evaluated using a protocol based on the reaction, under conditions of alkaline pH, between the phenolic compounds eventually present in the storage solution and diazonium salts.
The reaction product is a stable chromophore that can be detected and quantified by absorbance analysis at a wavelength of 480 nm. The concentration of phenols present in the sample is quantified by an external calibration method with a catechin standard and is therefore expressed as a milirnolar concentration of catechin equivalent (mM).
The results are shown in Figure 1.
Totally, 160 ppm of phenolic compounds were released from a treated tissue in 9 months. The release occurs almost in the first 14 days after the treatment Concerning the toxic potential, it can be confined that the total amount of polyphenols leakage from the treated tissues does not result in any health risk in fact, it is lower than the concentration of polyphenols present in the human plasma following the uptake with the diet.
In-vitro calcification assay Leaflets from untreated (B) and FACTATh' treated (BT) commercial BHVs, native (WT) and FACTATN treated native aortic porcine leaflets (WT T) and alpha-Gal knockout porcine aortic leaflets (KO) were incubated in pooled normal human serum (Innovative Research, Peary Court Novi, MI) with 2% of penicillin and streptomycin for 14 days at arc. As a control, a set of samples was incubated in PBS in the same condition. After incubation, samples were washed twice in PBS
for 10 min and subjected to acid hydrolysis in HNO3 at 110 C for 12 h. Calcium evaluation was performed in hydrolyzed samples by inductively coupled plasma according to the directives of the EPA8010D method and expressed as pg Ca241mg of dry defatted weight (d.d.w.).
The results are reported in Figure 2.
FACTAlm treated BEN (BT) shows a decrease in the calcffic propensity of 90% (B
vs BT p<0.05) and of 44.4% (BT vs KO, p<0.05) when compared with untreated BHVs (B) and alpha-Gal knockout tissues (KO) respectively. Knockout tissue is considered the least calcifying biological support and is used as an absolute negative control in xenotransplant-induced calcification studies.
FACTADA treated BHV has been shown to calcify almost 50% less than the KO
standard. If the FACTAT" method is applied to a native tissue (WT T, not fixed with glutaraldehyde), the anti-calcifying effectiveness compared to the reference tissue KO rise to 85% (WT T
vs KO p<0.05).
Hydrodynamic Assessment The hydrodynamic performance of the valves was assessed under simulated pulsatile flow in a Vniitro Pulse Duplicator System (Vivito Labs Inc., Victoria, BC, Canada). The flow simulator was used to model the left side of the heart. The test valves were fitted into a custom-fabricated silicon holder (Figure3) and placed in the aortic position of the pulsatile flow system. A 25 mm Bjork-Shiley tilting disc valve was used in the mitral position as a reference valve. The testing was performed in 0.9% (w/v) NaCI at room temperature. The valves were tested under five pulsatile flow conditions (Table 1), according to ISO 5840-3. The flow conditions corresponded to cardiac outputs between 2.5-9 1/min. During testing, the diastolic/systolic pressure was set to 80/120 mm Hg, whereas the systolic duration occupied 35% of the cardiac cycle. At each flow condition the valves were preconditioned for 5 min, before the pressure and flow signals were recorded over 10 cycles at each flow condition for each valve group (FACTA"' treated BHVs, n=3;
untreated BHVs, n=2).
Flow condition Cycle rate Stroke volume (bpm) (ml) Table I ¨ Pulsatile flow conditions used in the hydrodynamic assessment.
The hydrodynamic performance of the valves was assessed in terms of the mean pressure drop (MPD) and peak pressure drop (PPD) across the valve, root mean square forward flow through the valve (QpiAs), peak forward flow through the valve (QPEAK), valve effective orifice area (EOA), reverse flow through the valve during valve closure and while the valve was fully closed, and valve energy losses. As defined in ISO 5840-3, the EOA was measured using only the volumetric flow rate and the pressure difference across the valve during the positive pressure interval of the forward flow phase. The results tor each test were averaged over the number of cycles recorded (n=10). The data was analyzed in Microsoft Excel and Prism 7 for Windows (v7.03, GraphPad Software Inc., California) and expressed as mean standard deviation (SD).
Two-sided unpaired !-test was used to assess significant differences between the treated and untreated groups, at the 0.05 confidence levels.
The MPD ¨ Qs profiles of the untreated and treated valves, averaged over 10 cycles at each flow condition, are illustrated in Figure 4A and 4B, respectively. Both valve groups demonstrated excellent repeatability and similar ORM - PD profiles between them.
The mean E0As of the treated and untreated valves calculated for each flow condition is illustrated in Figure 5. There was no statistically significant difference in EOA between the untreated and treated group, apart from flow condition 100/80 (bpm/sv), at which the treated group demonstrated a significantly smaller (p<0.05) EOA compared to the untreated one.
The PPD-QpEAK profiles of the untreated and treated valves, averaged over 10 cycles at each condition, are illustrated in Figure 6A and 6B, respectively. Both groups demonstrated similar PPD-QpEasx profiles.
The mean dynamic and static regurgitation volumes of the untreated and treated groups at each flow conditions are illustrated in Figure 7. The dynamic regurgitation (dosing volume) and static regurgitation (closed volume) for both groups were negative representing back-flow through the valves. In general, the regurgitation volumes were more significant for the lower flow conditions and increased with increasing flow rates. No statistically significant differences were found in the regurgitation volumes between the untreated and treated groups.
The mean energy losses for the treated and untreated groups are illustrated in Figure 8. With increasing flow condition, an opposite pattern was observed for the energy losses in the forward flow and closed phase. The lowest energy loss during the forward flow phase was observed for the low-flow condition (60/60) and, increased with increasing flow rates. In contrast, the highest energy loss during the dosed phase was observed for the low-flow condition and decreased with increasing flow rates. There was no significant difference in the energy losses between the untreated and treated groups, in any of the flow conditions tested.
Biomechanical Assessment Low-strain rate uniaxial tensie loading to failure was carried in a Instron tensile tester (5967 Dual Column Series) with a 100N load cell. One leaflet was excised from each valve and used to isolate a specimen with test dimensions 6x3 min (length x width). The thickness of the samples was measured at 3 points along their length, using a Mitutoyo thickness gauge and averaged. During testing, each sample was preloaded to 0.01 N, at a strain rate of 20 mm/min, and then loaded to failure at the same rate. The recorded load-extension response of each sample was converted to engineering stress-engineering strain. The stress-strain curves were used to calculate the elastic and collagen phase slopes, transition stress and strain, failure strain and ultimate tensile strength.
The data was analysed in Excel and expressed as mean SD. Two-sided unpaired t-test was used to assess significant differences between the treated and untreated groups at the 0.05 confidence level.
The mean biomechanical parameters of the FACTATh treated and untreated groups are shown in Figure 9. Significant differences between the treated and untreated groups were found in the case of the failure strain (p<0.05). No significant differences were found in any of the other parameters between the FACTAlm treated and untreated groups. Although no statistical significance was found in the case of the elastic phase slope (Figure 9A) and transition strain (Figure 9C) between the two groups, these parameters were shown to be increased (elastin phase slope) or decreased (transition strain) for the treated group compared to the untreated one. A
higher elastic phase and a lower transition strain would indicate a stiffer and less extensible material, respectively, under low strain.
In-vivo investigation on swine animal model FACTAns treated (n=5) and untreated (n=3) commercial Trifecta GT BHVs (St.Jude Medical, USA) were implanted in puknonary position in a pig animal model. After 1 month of follow-up, the BHVs were removed for investigation. Explanted BHVs were washed with two 15-minute steps in sterile PBS at 4 C and immediately photographed for macroscopic evaluation (Figure
10). Subsequently, the leaflets were individually excised from each valve. The cusps for the histological and immune-histochemical investigations were immediately included in OCT (Optimal Cutting Temperature) compound and the remaining leaflets were subjected to alpha-Gal quantification by ELISA test. A
non-implanted Trifecta BHV was used as a referred control.
Macroscopic visual examination As can be seen from Figure 10, the untreated commercial BHVs, compared to the FACTATM
treated ones, show the presence of a critical fibrous deposit and blood clots on the ventricular surface. These peculiar characteristics of untreated BHVs, together with the formation of a homogeneous and thick pannus both around the suture ring and on the aortic surface of the cusps are better detectable on Figure 11.
Histolonical analysis Tissues were embedded in OCT compound (Tissue Tek; Sakura Finetek, Tokyo, Japan), cryo-cooled in liquid nitrogen, and cut into 6-mm cryo-sections. Histological analyses were performed by the use of commercial kit from Bio-Optica (Milan, Italy) according to the indications provided by the manufacturer. The histo-kits used are listed in Table 2.
Histological Kit Detected components - Meaning Hematoxylin & Assessment of the general aspect of the connective tissue / detection of cellular Eosin component Von Kassa Evaluation of the presence of calcific deposits Rem Mallory Assessment of the general aspect of the connective tissue, particularly referred to Trichromic collagen and elasfin components.
Evaluation of the presence of fibrin deposition and structured thrombus.
Oil Red 0 Assessment of the presence of lipid infiltrates Table 2- Histological kits used and their experimental significance.
Generally, leaflets from untreated valves report the presence of a homogeneous fibrotic pannus on the ventricular surface as highlighted by the black arrows in Figure 12 (Box A
and E). A foreign body reaction is clearly visible in all the explanted cusps, both untreated (Figure 12) and FACTAnA
treated commercial BHVs (Figure 13). It should be noted that in untreated commercial valves the cellular component is able to penetrate the matrix (Fig. 12 box D and H).
The FACTATh treatment seems to be able to exert a barrier effect that counteracts the penetration into the inner stoma of the inflammatory cellular component (Fig. 13, box C) responsible for the subsequent degeneration of the extracellular matrix.
In the untreated valves, in the area subtended to the fibrous pannus and adjacent to the cellular layer it is possible to observe the presence of a rich lipid infiltrate, as reported in Figure 14 (box A, B, C and D), probably due to the action of rnonocytes incapable of processing LDL. The rnonocytes incorporate the lipid drops, but not being able to degrade them, become foam cells subsequently working as enucleation site for calcium deposition. The FACTAnA treatment guarantees preservation of the tissue from this critical condition (Fig. 14, box E, F, G
and H, no lipid infiltration are present).
As predictable from the massive presence of lipid infiltrates, the untreated commercial BHVs after 1 month of follow up in swine are markedly calcified, with evident calcium accumulations especially at the level of the external interfaces of the leaflets (Figure 15). Where large deposits of calcium are not evident, however, wide spreads of micro-calcifications affecting the internal portion of the stroma are reported (Fig. 15, box D, E, G and H).
The FACTAnd treated commercial BHVs are optimally preserved from calcium deposition, as can be seen in Figure 16.
In addition to the development of fibrous pannus, the untreated commercial valves showed a very strong propensity for the development of structured thrombi on the ventricular surface of the leaflets, as shown in Figure 17.
In particular, in Figure 18 is reported a panel showing the presence of a fibrous pannus that culminates in a structured thrombus formation.
At the Mallory Trichromic staining, the FACTAnd treated commercial BHVs do not report the presence of any abnormal fibrous formation such as pannus or structured thrombus (Figure 19). It is important to note the presence of pink/purple streaks inside the collagen matrix in some explanted samples (Fig. 19, box E and F, G and H), corresponding to the elastic fibers.
Interestingly, such elastic fibers are never visible in the explants of untreated commercial BHVs.
A commercial BHV, not implanted in the animal model, was histologically processed as a reference control. From the investigations emerge how this tissue does not show any foreign body reaction (Figure 20, box A and B), and consequently, it is not affected by the development of fibrotic pannus or thrombi (Fig. 20, box E and F). There are also no lipid infiltrations or calcified deposits (Fig. 20, box C and D and G and H respectively). It should be noted that the elastic fibers are well represented by the Mallory staining (Fig. 20, box E and F), similar to that found for the FACTATh treated commercial BHV (Fig. 19, box E and F, G and H).
Figure 21 shows a panel of different histological staining of a FACTAlm treated commercial BHVs.
This panel summarizes all the improvements that the FACTATMA treatment provides to the bioprosthetic tissue. It is clearly evident the barrier effect exerted by the treatment; in fact, the host cellular population is unable to penetrate within the matrix (box B and D).
This barrier effect is further confirmed by the absence of any lipid infiltration as showed in the box E. Finally, the tissue is free from calcific deposition (box F).
Resistance to bacterial adhesion The anti-adhesive bacterial activity on FACTAm treated and untreated commercial valves was evaluated with the bacterial species of Staphylococcus auteus ATCC 6538 (gram-positive). The bacteria were grown overnight in Tryptic Soy Broth (TSB) at of 37 C. The total bacterial load was assessed by 10-factor serial dilutions in TSB (10-1 to 10-7), sown in Petri dishes with appropriate selective medium (MSA-Mannitol Selective Agar) and kept in overnight incubator. At the end of the incubation, the units forming colony (UFC) were counted to determine the effective concentration of the microorganism. Furthermore, the value of optical density at 600 nm (0D600) was determined from each tiled dilution, in order to verify the linearity between the latter and the effective microbial load of the broth. Commercial FACTATIA treated and untreated BHVs leaflets were cut with a punch for biopsies (3 mm in diameter), in order to obtain the same useful surface for bacterial adhesion. The tissue punches thus obtained were washed with PBS
and incubated overnight at room temperature in PBS + gentamicin (300 pg/mL) under moderate but constant agitation.
After overnight incubation, the commercial BHVs tissue punches were washed extensively in PBS
to remove any remaining antibiotics. Subsequently, the FACTATh treated and untreated samples were exposed to S. aureus bacterial suspensions (bacterial load 1 X 107 CFU/mL) for 90 minutes at room temperature under moderate but constant agitation. At the end of the incubation, the tissue samples were subject to three moderate vortexing mix to facilitate the detachment of the loosely bound bacteria.
Subsequently, the different tissue punches were homogenized by Ultratunax and serial dilutions of the obtained homogenates, plated in Petri dishes containing the appropriate selective growth media. Finally, after 24 hours of incubation at 37 C, the colony-formed units were counted for each type of samples. The bacterial anti-adhesive activity was calculated using the following formula:
cr IcriMn-) 100]
Where CT is the bacterial charge of the tissue sample obtained from a commercial BHV treated with the FACTAn" technology and CNT is the one achieved in tissue pinches from commercial BHVs (untreated).
As shown in Figure 22, the FACTAna treatment significantly limits the adhesive capacity of S.
aureus (reduction of 96 4%) on the tissue surface.
Calcification mitigation properties in wild-type murine animal model To evaluate the calcification mitigation properties of FACTATh, technologies, treated (F) and untreated (C) pericardial bloprosthetic heart valve (BHV) leaflets from Trifecta GTTIA model (Abbott/St. Jude), were implanted sub-dermally in the back of C57BI/6 wild-type mice. A total of 30 mice were enrolled, and each animal received a single specimen. Tissue samples were explanted after 1.2 and 4 months of follow-up. As a control sample, calcium quantification was also carried out in off-the-shelves original Trifecta GTTh valve leaflets, labelled UN
(unimplanted). Calcium content was evaluated by Inductive Coupled Plasma (ICP - a specific type of mass spectroscopy with a calcium quantification threshold of 0.048 pg/mg of tissue) and expressed as pg/mg of dry defatted weight (d.d.w.).
To further confirm the calcium quantification as carried on by ICP analysis, histological preparations of FACTAnI treated (F) and untreated (C) samples after 4 months of follow-up were performed. Histological preparations were analyzed by Von Kossa staining, a specific technique to highlight calcium deposition in biological tissues The results of the calcium quantification by ICP analysis are shown in figure 23.
The untreated original samples (C) showed a considerable tendency to calcify just after the first month of implantation. The trend continues significantly during the follow-up resulting in a calcium deposition of 7A 7 pg/mg of d.d_w_ as quantified at the end of the fourth month of the implant (Table 1). Conversely, the FACTATh treated samples (F) report a negligible amount of calcium even after 4 months follow-up. Noteworthy, the calcium content in the F samples does not exceed significantly the total calcium detected in the UN, confirming no calcium uptake over time (Table 1).
FACTAn" TREATED 0.0246 0.02 0.1378 0.04 0.0425 0.01 UNTREATED 0.8623 1.5.01 6.166 0.01 7.1787 0.23 UNIMPLANTED 0.11921 0.05 Table 1¨ Average of calcium content expressed as pg/mg of d.d.w. in FACTAIN
treated (F) and untreated (C) samples after different follow-up.
The results of the Von Kossa histological staining are shown in figure 24.
Calcium deposits are recognizable as black spots (indicated, where present, by the arrows).
According to the ICP analysis, FACTAn, treated samples (F) do not exhibit any significant presence of calcium deposition after 4 months follow-up in the mice sub-cutis.
On the other hand, original untreated control samples (C), report the presence of different calcium aggregates, some even of considerable dimension (C4 box).
Calcification mitigation properties in an alpha-Gal knockout murine animal model The purpose of the test was the evaluation of the calcium uptake in leaflets excised from a commercially available Trifecta GTTM BHV and its FACTATM treated counterparts, once implanted in an alpha-Gal knockout (KO) =mine animal model. The KO mouse is a specifically developed BCI-owned murine model genetically modified to silence the expression of the alpha-Gal xenoantigen_ Alpha-Gal KO mice are characterized by having an immunological response mechanism similar to the human where the alpha-Gal antigen stimulates the production of specific anti-Gal antibodies. Leaflets were implanted sub-cutis in the back of C57B1/8 alpha-Gal KO mice.
Calcium content was evaluated by Inductive Coupled Plasma (ICP - a specific type of mass spectroscopy) and expressed as pg/mg of dry defatted weight (d.d.w.). FACTATM
treated (F) and original leaflets (C), excised from commercial Trifecta GT valves (Abbott/St.Jude), were implanted subdermally in the back of wild type (WT) and knock-out (KO) for alpha-Gal mice. Each animal received a single specimen.
As a control sample, calcium quantification was also carried out in off-the-shelves original TRIFECTA GTTM valve leaflets, labelled UN (uninmplanted).
The results are shown in figure 25.
The amount of calcium determined in the F samples at 1-month as well as 2-months of follow-up was negligible as it is lower than the ICP quantification threshold (0.048 pg/mg). The calcium content in the F samples does not exceed the total calcium detected in the UN, confirming no calcium uptake at land 2 months follow-up. Conversely, the G specimens implanted in KO show a pro-calcific effect by reporting a significant and homogenous presence of calcium. The results demonstrate a clear role of the alpha-Gal in promoting calcium deposition in the KO mice as it happens into humans.
FACTADA treatment proves to be effective in counteracting the calcification even in a critical physiological system like the alpha-Gal KO model.
From the above disclosure, the advantages offered by the present invention will be immediately evident to the person skilled in the art.
For instance, the invention method is capable of limiting the deposition of calcium salts, therefore preventing the formation of episodes of calcific dystrophy of the valve.
Also, the invention method has shown to protect the treated cardiovascular bio-prostheses against the formation of blood clots and structured thrombi.
The method of the invention allows to avoid the lipoproteins infiltration from blood circulation and the consequent onset of cell-mediated inflammably tissue response in the treated cardiovascular bio-prostheses.
Finally, with the invention a method has been developed to avoid colonization by bacteria, preserving the cardiovascular tissues from the onset of the endocarditis.
The method disclosed in the present invention proved to be very stable and safe.
The collected evidence show that it did not significantly alter the hydrodynamic and biomechanical integrity of the treated valves. Nevertheless, the values of the hydrodynamic parameters obtained for the treated valves range within the values indicated in the ISO 5840-3 standard.
Also, the method proved to be able to inhibit the formation of calcified deposits both at the in-vitro and in-vivo investigations. The BHVs treated with FACTAlu were clearly non-thrombogenic and protected from cellular and lipid infiltration.
Last but not least, with the invention a method has been devised that can be carried out with conventional devices and machines.
As for the invention kit, it is aimed at the autonomous treatment of bioprosthetic substitutes that are already prepared, with a method according to the invention as described above, useful for health facilities like clinics and hospitals.
The invention is susceptible of numerous modifications and variations, all of which are within the scope of the appended claims.
Moreover, all the elements may be substituted by other, technically equivalent elements_
non-implanted Trifecta BHV was used as a referred control.
Macroscopic visual examination As can be seen from Figure 10, the untreated commercial BHVs, compared to the FACTATM
treated ones, show the presence of a critical fibrous deposit and blood clots on the ventricular surface. These peculiar characteristics of untreated BHVs, together with the formation of a homogeneous and thick pannus both around the suture ring and on the aortic surface of the cusps are better detectable on Figure 11.
Histolonical analysis Tissues were embedded in OCT compound (Tissue Tek; Sakura Finetek, Tokyo, Japan), cryo-cooled in liquid nitrogen, and cut into 6-mm cryo-sections. Histological analyses were performed by the use of commercial kit from Bio-Optica (Milan, Italy) according to the indications provided by the manufacturer. The histo-kits used are listed in Table 2.
Histological Kit Detected components - Meaning Hematoxylin & Assessment of the general aspect of the connective tissue / detection of cellular Eosin component Von Kassa Evaluation of the presence of calcific deposits Rem Mallory Assessment of the general aspect of the connective tissue, particularly referred to Trichromic collagen and elasfin components.
Evaluation of the presence of fibrin deposition and structured thrombus.
Oil Red 0 Assessment of the presence of lipid infiltrates Table 2- Histological kits used and their experimental significance.
Generally, leaflets from untreated valves report the presence of a homogeneous fibrotic pannus on the ventricular surface as highlighted by the black arrows in Figure 12 (Box A
and E). A foreign body reaction is clearly visible in all the explanted cusps, both untreated (Figure 12) and FACTAnA
treated commercial BHVs (Figure 13). It should be noted that in untreated commercial valves the cellular component is able to penetrate the matrix (Fig. 12 box D and H).
The FACTATh treatment seems to be able to exert a barrier effect that counteracts the penetration into the inner stoma of the inflammatory cellular component (Fig. 13, box C) responsible for the subsequent degeneration of the extracellular matrix.
In the untreated valves, in the area subtended to the fibrous pannus and adjacent to the cellular layer it is possible to observe the presence of a rich lipid infiltrate, as reported in Figure 14 (box A, B, C and D), probably due to the action of rnonocytes incapable of processing LDL. The rnonocytes incorporate the lipid drops, but not being able to degrade them, become foam cells subsequently working as enucleation site for calcium deposition. The FACTAnA treatment guarantees preservation of the tissue from this critical condition (Fig. 14, box E, F, G
and H, no lipid infiltration are present).
As predictable from the massive presence of lipid infiltrates, the untreated commercial BHVs after 1 month of follow up in swine are markedly calcified, with evident calcium accumulations especially at the level of the external interfaces of the leaflets (Figure 15). Where large deposits of calcium are not evident, however, wide spreads of micro-calcifications affecting the internal portion of the stroma are reported (Fig. 15, box D, E, G and H).
The FACTAnd treated commercial BHVs are optimally preserved from calcium deposition, as can be seen in Figure 16.
In addition to the development of fibrous pannus, the untreated commercial valves showed a very strong propensity for the development of structured thrombi on the ventricular surface of the leaflets, as shown in Figure 17.
In particular, in Figure 18 is reported a panel showing the presence of a fibrous pannus that culminates in a structured thrombus formation.
At the Mallory Trichromic staining, the FACTAnd treated commercial BHVs do not report the presence of any abnormal fibrous formation such as pannus or structured thrombus (Figure 19). It is important to note the presence of pink/purple streaks inside the collagen matrix in some explanted samples (Fig. 19, box E and F, G and H), corresponding to the elastic fibers.
Interestingly, such elastic fibers are never visible in the explants of untreated commercial BHVs.
A commercial BHV, not implanted in the animal model, was histologically processed as a reference control. From the investigations emerge how this tissue does not show any foreign body reaction (Figure 20, box A and B), and consequently, it is not affected by the development of fibrotic pannus or thrombi (Fig. 20, box E and F). There are also no lipid infiltrations or calcified deposits (Fig. 20, box C and D and G and H respectively). It should be noted that the elastic fibers are well represented by the Mallory staining (Fig. 20, box E and F), similar to that found for the FACTATh treated commercial BHV (Fig. 19, box E and F, G and H).
Figure 21 shows a panel of different histological staining of a FACTAlm treated commercial BHVs.
This panel summarizes all the improvements that the FACTATMA treatment provides to the bioprosthetic tissue. It is clearly evident the barrier effect exerted by the treatment; in fact, the host cellular population is unable to penetrate within the matrix (box B and D).
This barrier effect is further confirmed by the absence of any lipid infiltration as showed in the box E. Finally, the tissue is free from calcific deposition (box F).
Resistance to bacterial adhesion The anti-adhesive bacterial activity on FACTAm treated and untreated commercial valves was evaluated with the bacterial species of Staphylococcus auteus ATCC 6538 (gram-positive). The bacteria were grown overnight in Tryptic Soy Broth (TSB) at of 37 C. The total bacterial load was assessed by 10-factor serial dilutions in TSB (10-1 to 10-7), sown in Petri dishes with appropriate selective medium (MSA-Mannitol Selective Agar) and kept in overnight incubator. At the end of the incubation, the units forming colony (UFC) were counted to determine the effective concentration of the microorganism. Furthermore, the value of optical density at 600 nm (0D600) was determined from each tiled dilution, in order to verify the linearity between the latter and the effective microbial load of the broth. Commercial FACTATIA treated and untreated BHVs leaflets were cut with a punch for biopsies (3 mm in diameter), in order to obtain the same useful surface for bacterial adhesion. The tissue punches thus obtained were washed with PBS
and incubated overnight at room temperature in PBS + gentamicin (300 pg/mL) under moderate but constant agitation.
After overnight incubation, the commercial BHVs tissue punches were washed extensively in PBS
to remove any remaining antibiotics. Subsequently, the FACTATh treated and untreated samples were exposed to S. aureus bacterial suspensions (bacterial load 1 X 107 CFU/mL) for 90 minutes at room temperature under moderate but constant agitation. At the end of the incubation, the tissue samples were subject to three moderate vortexing mix to facilitate the detachment of the loosely bound bacteria.
Subsequently, the different tissue punches were homogenized by Ultratunax and serial dilutions of the obtained homogenates, plated in Petri dishes containing the appropriate selective growth media. Finally, after 24 hours of incubation at 37 C, the colony-formed units were counted for each type of samples. The bacterial anti-adhesive activity was calculated using the following formula:
cr IcriMn-) 100]
Where CT is the bacterial charge of the tissue sample obtained from a commercial BHV treated with the FACTAn" technology and CNT is the one achieved in tissue pinches from commercial BHVs (untreated).
As shown in Figure 22, the FACTAna treatment significantly limits the adhesive capacity of S.
aureus (reduction of 96 4%) on the tissue surface.
Calcification mitigation properties in wild-type murine animal model To evaluate the calcification mitigation properties of FACTATh, technologies, treated (F) and untreated (C) pericardial bloprosthetic heart valve (BHV) leaflets from Trifecta GTTIA model (Abbott/St. Jude), were implanted sub-dermally in the back of C57BI/6 wild-type mice. A total of 30 mice were enrolled, and each animal received a single specimen. Tissue samples were explanted after 1.2 and 4 months of follow-up. As a control sample, calcium quantification was also carried out in off-the-shelves original Trifecta GTTh valve leaflets, labelled UN
(unimplanted). Calcium content was evaluated by Inductive Coupled Plasma (ICP - a specific type of mass spectroscopy with a calcium quantification threshold of 0.048 pg/mg of tissue) and expressed as pg/mg of dry defatted weight (d.d.w.).
To further confirm the calcium quantification as carried on by ICP analysis, histological preparations of FACTAnI treated (F) and untreated (C) samples after 4 months of follow-up were performed. Histological preparations were analyzed by Von Kossa staining, a specific technique to highlight calcium deposition in biological tissues The results of the calcium quantification by ICP analysis are shown in figure 23.
The untreated original samples (C) showed a considerable tendency to calcify just after the first month of implantation. The trend continues significantly during the follow-up resulting in a calcium deposition of 7A 7 pg/mg of d.d_w_ as quantified at the end of the fourth month of the implant (Table 1). Conversely, the FACTATh treated samples (F) report a negligible amount of calcium even after 4 months follow-up. Noteworthy, the calcium content in the F samples does not exceed significantly the total calcium detected in the UN, confirming no calcium uptake over time (Table 1).
FACTAn" TREATED 0.0246 0.02 0.1378 0.04 0.0425 0.01 UNTREATED 0.8623 1.5.01 6.166 0.01 7.1787 0.23 UNIMPLANTED 0.11921 0.05 Table 1¨ Average of calcium content expressed as pg/mg of d.d.w. in FACTAIN
treated (F) and untreated (C) samples after different follow-up.
The results of the Von Kossa histological staining are shown in figure 24.
Calcium deposits are recognizable as black spots (indicated, where present, by the arrows).
According to the ICP analysis, FACTAn, treated samples (F) do not exhibit any significant presence of calcium deposition after 4 months follow-up in the mice sub-cutis.
On the other hand, original untreated control samples (C), report the presence of different calcium aggregates, some even of considerable dimension (C4 box).
Calcification mitigation properties in an alpha-Gal knockout murine animal model The purpose of the test was the evaluation of the calcium uptake in leaflets excised from a commercially available Trifecta GTTM BHV and its FACTATM treated counterparts, once implanted in an alpha-Gal knockout (KO) =mine animal model. The KO mouse is a specifically developed BCI-owned murine model genetically modified to silence the expression of the alpha-Gal xenoantigen_ Alpha-Gal KO mice are characterized by having an immunological response mechanism similar to the human where the alpha-Gal antigen stimulates the production of specific anti-Gal antibodies. Leaflets were implanted sub-cutis in the back of C57B1/8 alpha-Gal KO mice.
Calcium content was evaluated by Inductive Coupled Plasma (ICP - a specific type of mass spectroscopy) and expressed as pg/mg of dry defatted weight (d.d.w.). FACTATM
treated (F) and original leaflets (C), excised from commercial Trifecta GT valves (Abbott/St.Jude), were implanted subdermally in the back of wild type (WT) and knock-out (KO) for alpha-Gal mice. Each animal received a single specimen.
As a control sample, calcium quantification was also carried out in off-the-shelves original TRIFECTA GTTM valve leaflets, labelled UN (uninmplanted).
The results are shown in figure 25.
The amount of calcium determined in the F samples at 1-month as well as 2-months of follow-up was negligible as it is lower than the ICP quantification threshold (0.048 pg/mg). The calcium content in the F samples does not exceed the total calcium detected in the UN, confirming no calcium uptake at land 2 months follow-up. Conversely, the G specimens implanted in KO show a pro-calcific effect by reporting a significant and homogenous presence of calcium. The results demonstrate a clear role of the alpha-Gal in promoting calcium deposition in the KO mice as it happens into humans.
FACTADA treatment proves to be effective in counteracting the calcification even in a critical physiological system like the alpha-Gal KO model.
From the above disclosure, the advantages offered by the present invention will be immediately evident to the person skilled in the art.
For instance, the invention method is capable of limiting the deposition of calcium salts, therefore preventing the formation of episodes of calcific dystrophy of the valve.
Also, the invention method has shown to protect the treated cardiovascular bio-prostheses against the formation of blood clots and structured thrombi.
The method of the invention allows to avoid the lipoproteins infiltration from blood circulation and the consequent onset of cell-mediated inflammably tissue response in the treated cardiovascular bio-prostheses.
Finally, with the invention a method has been developed to avoid colonization by bacteria, preserving the cardiovascular tissues from the onset of the endocarditis.
The method disclosed in the present invention proved to be very stable and safe.
The collected evidence show that it did not significantly alter the hydrodynamic and biomechanical integrity of the treated valves. Nevertheless, the values of the hydrodynamic parameters obtained for the treated valves range within the values indicated in the ISO 5840-3 standard.
Also, the method proved to be able to inhibit the formation of calcified deposits both at the in-vitro and in-vivo investigations. The BHVs treated with FACTAlu were clearly non-thrombogenic and protected from cellular and lipid infiltration.
Last but not least, with the invention a method has been devised that can be carried out with conventional devices and machines.
As for the invention kit, it is aimed at the autonomous treatment of bioprosthetic substitutes that are already prepared, with a method according to the invention as described above, useful for health facilities like clinics and hospitals.
The invention is susceptible of numerous modifications and variations, all of which are within the scope of the appended claims.
Moreover, all the elements may be substituted by other, technically equivalent elements_
Claims (23)
1. A method for preventing the formation of calcified deposits in or inside an isolated biological matrix, characterized in that it comprises the step of contading said biological matrix with a solution comprising a mixture of phenolic compounds.
2. The method according to the preceding daim, wherein said contacting is performed for a period of less than two hours at the temperature of 35 rc in the dark.
3. The method according to the preceding claim, wherein said solution comprising a mixture of phenolic compounds comprises a mixture of phenylpropanoids selected in the group comprising:
simple phenols, phenoic aldehydes, phenolic acids, phenylamines, phenol compounds, flavonoids, phenylpropanokls and tannins.
simple phenols, phenoic aldehydes, phenolic acids, phenylamines, phenol compounds, flavonoids, phenylpropanokls and tannins.
4. The method according to the preceding claim 1 or 2, wherein said solution comprising a mixture of phenolic cornpounds comprises a mixture of phenylpropanoids seleted in the group comprising: resveratrol, abin, cyanarin, epigallocatechin, tannic acid, caffeic acid, chlorogenic acid, hydroxytyrosol, rosmarinic acid, narigenin, gallic acid, hesperidin, quinic acid, eleonolic acid, pinoresinol, luteolin, apigenin, tangeritin, isorhamnetin, kaempferol, myricetin, eriodictyol, hesperetin, naringenin, theaflavin, thearubigins, daidzein, genistein, glycitein, pterostilbene, delphinidin, malvidin, pelargonidin, peonklin, chicoric acid, ferulic acid, salicylic acid.
5. The method according to any one of the preceding claims, wherein the sokrtion of the phenolic compound further includes a suitable buffer.
6. The method according to the preceding claim, wherein within the solution each phenylpropanoid is comprised in a concentration of about 0_2-5 mg/ml 0_5 mg/ml.
7. The method according to any one of the preceding claims, wherein said solution comprises one of the followina combinations of ohenvlorooanoids:
8. The method according to any one of the preceding claims, wherein said isolated biological matrix is represented by vessels, cardiac valves, tendons, ligaments, pericardium, muscular fasciae, dura meter, tympanic membrane, intestinal submucosa, cartilages, adipose tissue and bone tissue, pelvic abdominal and breast tissue, cardiovascular prostheses like cardiac valves and pericardial tissue patches.
9. The method according to the preceding claim, wherein said isolated biological matrix is represented by a trans-calheter valve implantation (TAVI) prostheses or surgical valve prostheses.
10. The method acconding to any one of the preceding claims, which provides one or more of: inactivates xenoantigens in biological matrixes, prevents the thrombus formation on or inside said biological matrix, prevents the lipid infiltration into a biological matrix, prevents the onset of inflammatory process mediated by the cellular component, prevents the biofouling processes on a biological matrix.
11. An isolated biological matrix obtained according to the method of the any one of the preceding claims 1 to 10.
12. An isolated biological matrix obtained according to the method of the any one of the preceding claims 1 to 10 for use in the treatment of heart diseases in the medical, biomedical and/or veterinary field.
13. A solution comprising a mixture of phenolic compounds for use in the prevention of the formation of calcified deposits in an isolated biological matrix.
14. The solution comprising a mixture of phenolic compounds for use in the prevention of the formation of calcified deposits in an isolated biological matrix according to the preceding claim, wherein said solution comprises a mixture of phenylpropanoids selected in the group comprising:
simple phenols, phenolic aldehydes, phenolic acids, phenylamines, phenol compounds, flavonoids, phenylpropanoids and tannins.
simple phenols, phenolic aldehydes, phenolic acids, phenylamines, phenol compounds, flavonoids, phenylpropanoids and tannins.
15. The solution according to claim 13 or 14, comprising a mixture of phenolic compounds comprises a mixture of phenylpropanoids seleted in the group comprising:
resveratrol, aloin, cyanarin, epigallocatechin, tannic acid, caffeic acid, chlorogenic acid, hydroxytyrosol, rosmarinic acid, narigenin, gallic acid, hesperidin, quinic acid, eleonolic acid, pinoresinol, luteolin, apigenin, tangeritin, isorhamnetin, kaempferol, myricetin, eriodictyol, hesperetin, naringenin, theaflavin, thearubigins, daidzein, genistein, glycitein, pterostilbene, delphinidin, malvidin, pelargonidin, peonidin, chicoric acid, ferulic acid, salicylic acid.
resveratrol, aloin, cyanarin, epigallocatechin, tannic acid, caffeic acid, chlorogenic acid, hydroxytyrosol, rosmarinic acid, narigenin, gallic acid, hesperidin, quinic acid, eleonolic acid, pinoresinol, luteolin, apigenin, tangeritin, isorhamnetin, kaempferol, myricetin, eriodictyol, hesperetin, naringenin, theaflavin, thearubigins, daidzein, genistein, glycitein, pterostilbene, delphinidin, malvidin, pelargonidin, peonidin, chicoric acid, ferulic acid, salicylic acid.
16. The solution according to any one of the preceding claims 13 to 15, wherein the solution of the phenolic compound further includes a suitable buffer.
17. The solution according to the preceding claim, wherein within the solution each phenylpropanoid is comprised in a concentration of about 0.2-5 mg/ml 0.5 mg/ml.
18. The solution according to any one of the preceding claims 13 to 17, wherein said solution comprises one of the following combinations of phenylpropanoids:
19. An isolated biological matrix obtained according to the method of any one of claims 1 to for use in the treatment of heart diseases in the medical, biomedical and/or veterinary field.
20. The isolated biological matrix according to the preceding claim, which is represented by a trans-catheter valve implantation (TAV1) prostheses or surgical valve prostheses_
21. A method for the treatment of heart diseases in humans or animals comprising the use of an isolated biological matrix obtained according to the method any one of claims 1 to 10.
22. The method for the treatment of heart diseases in humans or animals according to the preceding claim, wherein said biological matrix is represented by a trans-catheter valve implantation (TAVI) prostheses or surgical valve prostheses.
23. A kit for performing the method of any one of claims 1 to 10, comprising:
- a container containing a suitable buffer, - a container containing a suitable quantity of a solution according to any one of claims 13 to 18 be dissolved in said buffer, - one or more containers containing the washing buffers;
- an instniction booldet containing the description of the timings and modes for perfoffning said method.
- a container containing a suitable buffer, - a container containing a suitable quantity of a solution according to any one of claims 13 to 18 be dissolved in said buffer, - one or more containers containing the washing buffers;
- an instniction booldet containing the description of the timings and modes for perfoffning said method.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102019000007094 | 2019-05-22 | ||
IT201900007094 | 2019-05-22 | ||
PCT/IB2020/054885 WO2020234845A1 (en) | 2019-05-22 | 2020-05-22 | Method for preventing the formation of calcified deposits and for inactivating xenoantigens in biological matrices |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3138296A1 true CA3138296A1 (en) | 2020-11-26 |
Family
ID=67734776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3138296A Pending CA3138296A1 (en) | 2019-05-22 | 2020-05-22 | Method for preventing the formation of calcified deposits and for inactivating xenoantigens in biological matrices |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3972659A1 (en) |
JP (1) | JP2022534228A (en) |
KR (1) | KR20220016119A (en) |
CN (1) | CN113874052A (en) |
AU (1) | AU2020277763A1 (en) |
BR (1) | BR112021023413A2 (en) |
CA (1) | CA3138296A1 (en) |
IL (1) | IL288239A (en) |
MX (1) | MX2021014295A (en) |
WO (1) | WO2020234845A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113984820B (en) * | 2021-08-31 | 2023-05-05 | 中南大学湘雅二医院 | Reagent combination and method for improving calcification resistance of bovine pericardial valve material |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001021228A1 (en) | 1999-09-22 | 2001-03-29 | Baxter International Inc. | Cardiac valve and method for preparing a biological tissue |
US20040153145A1 (en) * | 2002-11-26 | 2004-08-05 | Clemson University | Fixation method for bioprostheses |
CN100360190C (en) * | 2005-11-30 | 2008-01-09 | 中国科学院上海硅酸盐研究所 | Method for preparing artificial biological valve with biological activity |
CN101161293A (en) * | 2006-10-12 | 2008-04-16 | 胡盛寿 | Resist calcification modified method of heterogeneity biological organization material |
ITPD20120029A1 (en) | 2012-02-09 | 2013-08-10 | Alessandro Gandaglia | METHOD FOR DETECTION OF ONE XENOANTIGEN IN FIXED FABRICS USED AS BIO-PROSTHETIC SUBSTITUTES |
US9283241B2 (en) * | 2012-07-10 | 2016-03-15 | Clemson University | Treatment to render implants resistant to diabetes |
ITUB20156019A1 (en) | 2015-11-30 | 2017-05-30 | Biocompatibility Innovation Soc A Responsabilita Limitata Semplificata | METHOD FOR THE INACTIVATION OF XENOANTIGENES IN BIOLOGICAL FABRICS |
US11344575B2 (en) * | 2016-08-15 | 2022-05-31 | Summit Innovation Labs, LLC | Vascular calcification prevention and treatment |
CN107349215A (en) * | 2017-08-30 | 2017-11-17 | 江南大学 | Application of the Vaccarin in anti-angiogenic calcification medicine is prepared |
CN108498869B (en) * | 2018-04-08 | 2020-12-25 | 中国医学科学院生物医学工程研究所 | Polyphenol crosslinking agent and application thereof in preparation of anti-calcification biological valve |
-
2020
- 2020-05-22 EP EP20728220.3A patent/EP3972659A1/en active Pending
- 2020-05-22 AU AU2020277763A patent/AU2020277763A1/en active Pending
- 2020-05-22 MX MX2021014295A patent/MX2021014295A/en unknown
- 2020-05-22 WO PCT/IB2020/054885 patent/WO2020234845A1/en active Application Filing
- 2020-05-22 BR BR112021023413A patent/BR112021023413A2/en unknown
- 2020-05-22 JP JP2021569455A patent/JP2022534228A/en active Pending
- 2020-05-22 KR KR1020217041930A patent/KR20220016119A/en unknown
- 2020-05-22 CN CN202080037451.6A patent/CN113874052A/en active Pending
- 2020-05-22 CA CA3138296A patent/CA3138296A1/en active Pending
-
2021
- 2021-11-18 IL IL288239A patent/IL288239A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2021014295A (en) | 2022-01-06 |
IL288239A (en) | 2022-01-01 |
BR112021023413A2 (en) | 2022-01-04 |
KR20220016119A (en) | 2022-02-08 |
WO2020234845A1 (en) | 2020-11-26 |
EP3972659A1 (en) | 2022-03-30 |
JP2022534228A (en) | 2022-07-28 |
AU2020277763A1 (en) | 2021-12-16 |
CN113874052A (en) | 2021-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11951078B2 (en) | Method for preventing the formation of calcified deposits and for inactivating xenoantigens in biological matrices | |
CA2345799C (en) | Process for reducing mineralization of tissue used in transplantation | |
EP2077718B2 (en) | Biological tissue for surgical implantation | |
US6214055B1 (en) | Method and kit for rapid preparation of autologous tissue medical devices | |
JP3797673B2 (en) | Method for treating implantable biological tissue to reduce calcification and bioprosthesis treated in such a manner | |
US6471723B1 (en) | Biocompatible prosthetic tissue | |
US20160270896A1 (en) | Double cross-linkage process to enhance post-implantation bioprosthetic tissue durablity | |
Goecke et al. | In vivo performance of freeze-dried decellularized pulmonary heart valve allo-and xenografts orthotopically implanted into juvenile sheep | |
US20030118981A1 (en) | Process for reducing mineralization of tissue used in transplantation | |
Schoen et al. | Pathological calcification of biomaterials | |
CA3138296A1 (en) | Method for preventing the formation of calcified deposits and for inactivating xenoantigens in biological matrices | |
DK1978978T3 (en) | Biocompatible tissue graft for implantation as well as the process for its preparation | |
JP7169645B2 (en) | Method for inactivating heterologous antigens in living tissue | |
RU2633544C1 (en) | Method for manufacture of valve-containing conduit from cattle jugular vein | |
Tam | Novel chemical crosslinking to stabilize extracellular matrix for bioprosthetic heart valve materials to resist calcification and structural degradation | |
Zhang et al. | Implantation of a modified stented bovine pulmonary valve in a beating heart sheep model | |
Tripi | Stabilization of extracellular matrix components in bioprosthetic heart valves using neomycin and pentagalloyl glucose enhanced crosslinking | |
WEBER | GENERAL SURGICAL PROBLEMS OF TISSUE TRANSPLANTATION | |
Isenburg | Stabilization of vascular elastin by treatment with tannins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20240412 |